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pAs in past years, this Highlights paper takes the place of the
Editor’s Page and was assembled by the Associate Editors
based on the papers that they perceived had or would have
the greatest impact on cardiology. Space constraints result in
omitting many excellent papers, and we apologize in ad-
vance to those authors.
Antiplatelet and Antithrombin Therapy
Bonello et al. (1) investigated the relationship between
thrombotic events and platelet reactivity (PR) using the
vasodilator-stimulated phosphoprotein (VASP) index after
a loading dose of prasugrel in a prospective multicenter
study of 300 patients who underwent successful percutane-
ous coronary intervention (PCI) for acute coronary syn-
dromes (ACS). High on-treatment PR was defined as a
VASP index 50%. The mean VASP index after 60 mg of
prasugrel was 34.3 and high on-treatment PR was observed
in 76 patients. Patients experiencing thrombotic events after
PCI had significantly higher VASP indexes of PR com-
pared with those patients who were free of events (64% vs.
33%; p  0.001). Receiver-operating characteristic curve
nalysis found a cutoff value of 53.5% of the VASP index to
redict thrombotic events at 1 month (r 0.86, p 0.001).
hus, a significant number of patients undergoing PCI in
he setting of ACS do not achieve optimal PR inhibition
ith prasugrel.
Brar et al. (2) systematically evaluated the significance of
latelet reactivity during clopidogrel treatment on adverse
ardiovascular (CV) events by a meta-analysis using patient-
evel data for the VerifyNow P2Y12 assay in 6 studies with
,059 PCI patients. A peripheral resistance unit value230
as associated with a higher rate of the primary endpoint
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oints of death (HR: 1.66), myocardial infarction (MI)
HR: 2.04), and stent thrombosis (ST) (HR: 3.11).
In ARMYDA-6 MI (Antiplatelet Therapy of Reduction
f Myocardial Damage During Angioplasty-6 Myocardial
nfarction), Patti et al. (3) compared 600- and 300-mg
lopidogrel loading doses in 201 patients with ST-segment
levation myocardial infarction (STEMI). Infarct size was
ignificantly lower in the 600-mg regimen. In addition,
IMI (Thrombolysis In Myocardial Infarction) flow grade
3 after PCI was less frequent (5.8% vs. 16.3%, p 0.031),
eft ventricular ejection fraction (LVEF) at discharge was
mproved (52% vs. 49%, p  0.026), 30-day major adverse
ardiovascular events (MACE) were fewer (5.8% vs. 15%,
 0.049), and bleeding/entry site complications were not
ncreased (secondary endpoints).
Cheema et al. (4) characterized clopidogrel hypersensi-
ivity after PCI and described its successful management
ith oral prednisone without clopidogrel discontinuation.
lopidogrel hypersensitivity manifested as generalized ex-
nthema in 79%, localized skin reaction in 16%, and
ngioedema or urticaria in 5% of patients and is caused by a
ymphocyte-mediated delayed hypersensitivity in most pa-
ients. Allergenic cross-reactivity with ticlopidine, prasugrel,
r both is present in a significant number of patients with
lopidogrel hypersensitivity. Complete resolution of hyper-
ensitivity reaction was observed in 98% of patients with a
hort course of oral prednisone.
Dangas et al. (5) investigated the outcomes of switching
o bivalirudin after initial administration of heparin in
TEMI patients undergoing primary PCI in the
ORIZONS-AMI (Harmonizing Outcomes With Revas-
ularization and Stents in Acute Myocardial Infarction)
rial. At 30 days, major bleeding occurred in 7.6% of the
witch group versus 12.3% of the control group (p 
.0001). Switch patients had lower 30-day cardiac mortality
1.6% vs. 2.9%, p  0.04), major bleeding at 2 years (8.4%
s. 13.0%, p  0.0003), cardiac mortality (2.3% vs. 3.8%,
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tionated heparin to bivalirudin before primary PCI in
STEMI results reduced major bleeding and improved
early and late cardiac survival.
Regarding second-generation DES, the SPIRIT IV
(Clinical Evaluation of the Xience-V Everolimus-Eluting
Coronary Stent System) and COMPARE (Comparison of
the Everolimus Eluting Xience-V Stent With Paclitaxel
Eluting Taxus Liberté Stent in All Comers) trials compared
the 2-year results of EES to the paclitaxel-eluting stent
(6,7). SPIRIT IV was a randomized multicenter trial,
whereas COMPARE was a single-center study in real-life
patients. Both studies showed a clear benefit of everolimus
over paclitaxel that extended to 2 years. In an accompanying
editorial, Alfonso and Fernandez (8) commented that both
COMPARE and SPIRIT IV were large randomized clin-
ical trials that demonstrated the clinical superiority of
second-generation everolimus stents over existing paclitaxel
first-generation stents for hard clinical endpoints with a
long-term clinical follow-up.
Nakazawa et al. (9) studied the mechanism of late ST by
analyzing the pathological specimens from 174 patients who
died 30 days after receiving first-generation sirolimus and
paclitaxel-eluting stents. They observed localized strut hy-
persensitivity in sirolimus stents, whereas malapposition
secondary to excessive fibrin deposition was the underlying
cause of thrombosis with paclitaxel. In another study,
Nakazawa and colleagues examined both bare-metal stents
and DES from autopsy cases for evidence of neointimal
atherosclerotic disease in patients dying30 days after stent
mplantation (10). Neoatherosclerosis was significantly
reater (31% vs. 16%, p  0.001) and appeared earlier in
ES than bare-metal stents. The investigators concluded
hat neoatherosclerosis is a frequent finding in DES, occurs
arlier than in bare-metal stents, and may be another
ontributing factor to late ST. In an accompanying editorial,
uja (11) pointed out that the characteristics in the patients
eceiving DES versus bare-metal stents differed, leading to
aution in interpreting the vascular responses to these 2
ifference stents.
The relationship between the metabolic syndrome and
utcomes of PCI in the COURAGE (Clinical Outcomes
tilizing Revascularization and Aggressive Drug Evalua-
ion) trial was analyzed by Maron et al. (12). Of the 2,248
atients, 61% had metabolic syndrome and 34% diabetes.
eath and MI were highest in the group with both
isorders (25%, p  0.001). However, after adjusting for
ndividual components, metabolic syndrome was no longer
ignificantly associated with outcome. The addition of PCI
o optimal medical therapy did not significantly reduce the
isk of death or MI regardless of the presence of metabolic
yndrome or diabetes.
In another study directed toward improving outcomes
fter PCI, Suh et al. (13) reported the results of the
ILON-T (Influence of Cilostazol-Base Triple Antiplate-et Therapy on Ischemic Complication After Drug-Eluting gtent Implantation) trial. At 6-month follow-up, there was
o difference in the primary endpoint between dual aspirin/
lopidogrel alone or those agents plus cilostazol. Thus,
espite the greater reduction of platelet reactivity by cilosta-
ol, the outcome was not improved. In an accompanying
ditorial, Antoniucci (14) pointed out that the results of this
tudy were not consistent with those of 2 trials comparing
riple antiplatelet therapy with dual antiplatelet therapy in
atients at high risk of restenosis, such as those with
iabetes. Thus, he opined that the benefit of triple anti-
latelet therapy to enhance the results of percutaneous
ntervention remains uncertain.
ercutaneous Coronary Intervention
sai et al. (15) assessed the safety and efficacy of drug-
luting stents (DES) versus bare-metal stents in 283,593
atients 65 years of age related to renal function. In
ropensity-matched cohorts grouped by glomerular filtra-
ion rate, DES in patients with normal renal function was
ssociated with significant reductions in 30-month MI
nd death (HR: 0.73), but no difference in bleeding (HR:
.89). Lower MI and mortality rates were also observed
fter DES in all chronic kidney disease (CKD) subgroups
xcept MI in the long-term dialysis group. Decreased
ates of revascularization did not extend to any subgroup
f patients with CKD. They concluded that DES is safe
n all patients regardless of renal function and is associ-
ted with reduced rates of MI and death in some subsets
f CKD patients.
The prospective, open-label, multicenter randomized trial
XCELLENT (Efficacy of Xience/Promus Versus Cypher
o Reduce Late Loss After Stenting) by Park et al. (16)
ompared the angiographic outcomes of everolimus-eluting
tents (EES) and sirolimus-eluting stents in 1,428 patients.
he primary endpoint of in-segment late loss at 9 months
as noninferior. The incidence of clinical endpoints was
lso not statistically different between the 2 groups, includ-
ng target lesion failure (3.75% vs. 3.05%) and ST (0.37% vs.
.83%).
Baber et al. (17) evaluated the impact of the EES on the
requency of ST, target vessel revascularization, MI, and
ardiac death in a meta-analysis of 13 randomized con-
rolled trials comparing the EES to non–everolimus-eluting
ES with a follow-up of 21.7 months. EES significantly
educed ST (relative risk [RR]: 0.55), target vessel revascu-
arization (RR: 0.77), and MI (RR: 0.78). There was no
ifference in cardiac mortality. The treatment effect was
onsistent for different follow-up times and duration of
lopidogrel use.
In the RESOLUTE All-Comers trial (A Randomized
omparison of a Zotarolimus-Eluting Stent With an
verolimus-Eluting Stent for Percutaneous Coronary In-
ervention), Stefanini et al. (18) investigated the impact of
atient and lesion complexity on outcomes with newer-
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results did not differ between ZES and EES, regardless of
complexity. At 1 year, target lesion failure (TLR) was
similar in ZES- and EES-treated complex patients. Rates
of cardiac death, target-vessel MI, and clinically indicated
TLR were similar for both stent types among complex
patients. Definite or probable ST occurred in 20 (1.3%)
complex patients with no difference between ZES and
EES. Angiographic follow-up showed similar results for
ZES and EES in terms of in-stent percentage diameter
stenosis and in-segment binary restenosis in the complex
group. This study concluded that newer-generation ZES
and EES proved to be safe and effective, regardless of
complexity.
In the PLATINUM trial (A Prospective, Randomized,
Multicenter Trial to Assess an Everolimus-Eluting Coro-
nary Stent System [PROMUS Element] for the Treatment
of Up to Two De Novo Coronary Artery Lesions), Stone et
al. (19) evaluated the clinical outcomes with a novel plati-
num chromium EES compared with a predicate cobalt
chromium EES in 1,530 patients undergoing PCI. The
12-month rate of target lesion failure was noninferior with
cobalt chromium EES versus platinum chromium EES. By
intention-to-treat, there were no significant differences in
the 12-month rates of target lesion failure, cardiac death or
MI, TLR or definite or probable ST.
Chen et al. (20) investigated the difference in MACE at
12 months in coronary bifurcation lesions after double
kissing double crush or provisional stenting (PS) techniques
in 370 unselected patients. At 8 months, angiographic
restenosis rates in the main vessel and side branch were
significantly different between the double kissing (3.8% and
4.9%) and the PS groups (9.7% and 22.2%, p 0.036 and
p  0.001, respectively). Additional side branch stenting in
the PS group was required in 28.6% of lesions. Target vessel
revascularization of 6.5% in the double kissing group,
occurred less often than in the PS group (14.6%, p 
0.017). There were nonsignificant differences in MACE
and definite ST.
Park et al. (21) performed a 5-year follow-up in 3,042
patients with multivessel disease who underwent DES (n 
1,547) or coronary artery bypass graft (CABG) (n  1,495)
surgery for whom complete follow-up data were available
for a median of 5.6 years. After adjustment for differences in
baseline risk factors, 5-year risk of death (HR: 1.00, 95%
confidence interval [CI]: 0.76 to 1.32, p  0.99) and the
combined risk of death, MI, or stroke (HR: 0.97; 95% CI:
0.76 to 1.24, p  0.81) were similar between the DES
group and the CABG group. However, the rates of revas-
cularization were significantly higher in the DES group
(HR: 2.93, 95% CI: 2.20 to 3.90, p  0.001).
Nam et al. (22) investigated whether a fractional flow
reserve (FFR)-guided SYNTAX (Synergy Between Percu-
taneous Coronary Intervention With Taxus and Cardiac
Surgery) trial score (SS), termed “functional SYNTAX
score” (FSS), would predict clinical outcome better than rthe classic SS in patients with multivessel coronary artery
disease (CAD) undergoing PCI in 497 patients enrolled
in the FAME (Fractional Flow Reserve versus Angiog-
raphy for Multivessel Evaluation) study. FSS was deter-
mined by only counting ischemia-producing lesions (FFR
0.80). After determining the FSS for each patient, 32%
moved to a lower-risk group. MACE occurred in 9.0%,
11.3%, and 26.7% of patients in the low-, medium-, and
high-FSS groups, respectively (p  0.001). Only FSS and
procedure time were independent predictors of 1-year
MACE. FSS demonstrated a better predictive accuracy
for MACE than SS did. The investigators concluded that
recalculating SS by only incorporating ischemia-
producing lesions as determined by FFR decreases the
number of higher-risk patients and better discriminates
risk for adverse events in patients with multivessel CAD
undergoing PCI.
Lee et al. (23) evaluated the incidence, predictors, and
long-term outcomes of patients with in-stent restenosis
(ISR) after PCI with DES for unprotected left main
coronary artery (LMCA) disease in 509 consecutive pa-
tients, with 402 (80.1%) undergoing routine surveillance or
clinically driven angiographic follow-up. The overall inci-
dence of angiographic ISR in LMCA lesions was 17.6% (71
of 402 patients, 57 with focal-type and 14 with diffuse-type
ISR). Forty patients (56.3%) underwent repeated PCI, 10
(14.1%) underwent CABG, and 21 (29.6%) were treated
medically. During long-term follow-up (a median of 31.7
months), there were no deaths, 1 MI, and 6 repeated TLR.
The incidence of MACE was 14.4% in the medical group,
13.6% in the repeated PCI group, and 10.0% in the CABG
group (p  0.91). Multivariate analysis showed that the
occurrence of DES-ISR did not affect the risk of death or
MI. The long-term clinical prognosis of patients with
DES-ISR associated with LMCA stenting might be be-
nign, given that these patients were optimally treated with
the clinical judgment of the treating physician.
In the multicenter prospective LITRO study, de la
Torre Hernandez et al. (24) evaluated 354 consecutive
patients with intermediate lesions in unprotected LMCA
with intravascular ultrasound using minimum lumen area
(MLA) 6 mm2 as criterion for revascularization.
LMCA revascularization was performed in 90.5% (152 of
168) of patients with an MLA 6 mm2 and was deferred
n 96% (179 of 186) of patients with an MLA of 6
m2. At the 2-year follow-up, cardiac death-free survival
as 97.7% in the deferred group versus 94.5% in the
evascularized group (p  0.5), and event-free survival
as 87.3% versus 80.6%, respectively (p  0.3). Only 8
4.4%) deferred patients required subsequent LMCA
evascularization, none with an infarction. The investi-
ators concluded that angiographic measurements are not
eliable in the assessment of intermediate LMCA lesions,
nd that an MLA of 6 mm2 is a safe value for deferring
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Paravalvular leaks. Two studies demonstrated the medium-
term outcomes of percutaneous treatment of paravalvular
leaks. Sorajja et al. (25) determined the long-term clinical
efficacy of percutaneous repair of paravalvular prosthetic
regurgitation in 126 symptomatic patients. The 3-year
estimate for survival was 64.3%. Mortality occurred due
to cardiac, noncardiac, and unknown causes in 9.5%,
7.1%, and 5.6% of patients, respectively. Among survi-
vors, 72% of patients who had presented with heart
failure (HF) were free of severe symptoms and the need
for cardiac surgery. Severity of residual regurgitation was
not related to overall survival but was an important
determinant of other clinical events. For those with no,
mild, or moderate or severe residual regurgitation, 3-year
estimate of survival free of death or need for surgery was
63.3%, 58.3%, and 30.3% (p  0.01), respectively. Ruiz
et al. (26) reported results in 43 patients showing closure
was successful in 86% of leaks with improvement in New
York Heart Association (NYHA) functional class and
overall clinical success in 89% of these patients. The
survival rates for patients at 6, 12, and 18 months after
paravalvular leak closures were 91.9%, 89.2%, and 86.5%,
respectively. Freedom from cardiac-related death at 42
months following the procedure was 91.9%. These 2
studies demonstrate that percutaneous closure of symp-
tomatic paravalvular leaks may result in high rates of
acute and long-term success and is effective in managing
symptoms of HF and hemolytic anemia.
Transcatheter aortic valve replacement. Rodés-Cabau et
al. (27) studied 101 patients who underwent successful
transcatheter aortic valve replacement (TAVR) and
showed that TAVR was associated with some degree of
myocardial injury in 99% of the patients as determined by
a rise in cardiac troponin T and creatine kinase-
myocardial band. A larger myocardial injury was associ-
ated with a smaller improvement of LVEF. The degree of
rise in cardiac troponin T was an independent predictor
of cardiac mortality at 9 to 10 months of follow-up (HR:
1.14 per each increase of 0.1 g/l).
Rodés-Cabau et al. (28) also compared the incidence of
erebral embolism within 6 days of transapical versus
ransfemoral TAVR as evaluated by diffusion-weighted
agnetic resonance imaging (MRI) in 60 patients. A total
f 41 patients (68%) had 251 new cerebral ischemic lesions
t the post-procedure diffusion-weighted MRI, 19 patients
n the transfemoral group (66%) and 22 patients in the
ransapical group (71%; p  0.78). Most patients with new
schemic lesions had multiple lesions (median lesions per
atient: 3). There were no differences in lesion number and
ize between the transfemoral and transapical groups. No
aseline or procedural factors were found to be predictors of
ew ischemic lesions. Cerebral embolism was not associated
ith a measurable impairment in cognitive function. fWenaweser et al. (29) assessed the role of TAVR (n 
57) compared with medical treatment (MT) (n  78) and
urgical aortic valve replacement (SAVR) (n  107) in
atients with severe aortic stenosis (AS) (age: 81.7 years,
ean logistic European System for Cardiac Operative Risk
valuation: 22.3) as part of a prospective registry. Baseline
linical characteristics were similar among patients allocated
o MT and transcatheter aortic valve implantation, whereas
atients allocated to SAVR were younger and had a lower
redicted perioperative risk. Adjusted HRs for death were
.51 for TAVR compared with MT and 0.38 for TAVR
ompared with MT. Medical treatment, older age, periph-
ral vascular disease, and atrial fibrillation (AF) were signif-
cantly associated with all-cause mortality at 30 months in
he multivariate analysis. At 1 year, more patients undergo-
ng SAVR (92.3%) or transcatheter aortic valve implanta-
ion (93.2%) had NYHA functional class I/II as compared
ith patients with MT (70.8%, p  0.003).
Rudolph et al. (30) assessed the median 1-year outcomes
f 104 patients who were not surgical candidates undergo-
ng MitraClip (Abbott Vascular, Abbott Park, Illinois)
herapy for severe mitral regurgitation (MR). The MR
rade 2 was present at follow-up in 82.5%, left ventric-
lar (LV) end-diastolic and -systolic volumes were reduced,
nd forward stroke volumes were significantly increased.
mprovements in NYHA functional class were observed in
0% of patients, with 69% in class I or II; the majority
mproved in the 6-min walk test and quality of life.
stimates of mortality and rehospitalization were 22% and
1%, respectively. Forward stroke volume at discharge
redicted event-free survival.
Auricchio et al. (31) evaluated the safety, efficacy, and
ffect of MitraClip treatment on symptoms and LV remod-
ling in 51 nonresponders to cardiac resynchronization
herapy (CRT). Functional class and reverse LV remodeling
nd LVEF improved over 12 to 14 months. Overall mor-
ality at follow-up was 19.9 per 100 person-years.
Given the favorable findings regarding the use of the
itral clip (MitraClip), Siegel et al. (32) reported on the
cute hemodynamic effects of this therapeutic intervention.
hey studied 107 patients with cardiac catheterization
efore and immediately following percutaneous mitral valve
epair with the MitraClip device. They observed an in-
reased cardiac output and forward stroke volume as well as
decrease in systemic vascular resistance (p  0.001). Both
V end-diastolic pressure and volume were reduced. Thus,
itral valve repair with the MitraClip resulted in immediate
mprovement in cardiac hemodynamics.
Kenny et al. (33) evaluated the safety and effectiveness of
he Edwards SAPIEN Transcatheter heart valve (Edwards
ifesciences, Irvine, California) in the pulmonary position
n 36 patients with moderate-to-severe pulmonary regurgi-
ation with or without stenosis. Successful deployment was
chieved in 33 of 34 attempts. Conduit gradient decreased
rom 26.8 to 11.7 mm Hg (p  0.001). At 6-month
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rom reintervention was 97%.
TAVR represents a very promising strategy for manage-
ent of patients with AS who are not optimal surgical
andidates (34). Ewe et al. describe an important limitation
f TAVR, specifically the mismatch of valve size in some
atients undergoing this procedure. Patients with a mis-
atch in valve size have substantially less improvement in
he hemodynamic and clinical response to valve replace-
ent, findings that will require additional vigilance and
urther study as this procedure becomes more common in
he United States.
Leon et al. (35) in a consensus report from the Valve
cademic Research Consortium provided standardized
ndpoint definitions for transcatheter aortic valve implan-
ation clinical trials. These standardized endpoint defini-
ions should provide for consistency across the multiple
tudies currently being done in the evolving area of percu-
aneous valve implantation.
eripheral Arterial Disease and Stroke
chmidt et al. (36) evaluated paclitaxel-eluting balloons to
reat long lesions in 104 patients with critical limb ischemia
r severe claudication. At 378-day follow-up, clinical im-
rovement was present in 91.2%. Complete wound healing
ccurred in 74.2%, and limb salvage was 95% for patients
ith critical limb ischemia. The investigators concluded
hat early restenosis of long-segment infrapopliteal disease is
ignificantly less after treatment with paclitaxel-eluting
alloons than historical data using uncoated balloons.
Bonvini et al. (37) evaluated the technical feasibility,
afety, and 1-year efficacy of the endovascular treatment of
therosclerotic common femoral artery obstructions in 360
onsecutive patients. Chronic total common femoral artery
cclusions were recanalized in 60 cases (16.7%). Balloon
ngioplasty was performed as the primary intervention in
irtually all cases (98.6%), whereas stenting was needed for
uboptimal angioplasty results in 133 procedures (36.9%).
estenosis 50% and TLR were observed in 27.6% and
9.9% of procedures, respectively. This series suggests that
he percutaneous approach may be a valid alternative to surgery
or common femoral artery atherosclerotic obstructions.
Montorsi et al. (38) compared the rate of cerebral
icroembolization (MES) during carotid artery stenting in
3 consecutive patients with high-risk, lipid-rich plaque
andomized to carotid artery stenting with proximal protec-
ion (MO.MA system, Invatec Inc., Brescia, Italy) (n  26)
r distal protection with a filter (FilterWire EZ, Boston
cientific, Natick, Massachusetts). Transcranial Doppler
nd diffusion-weighted MRI were performed. The
O.MA system significantly reduced mean MES counts
p  0.0001) during lesion crossing, stent crossing, stent
eployment, stent dilation, and total MES. By multivariate
nalysis, the type of brain protection was the only indepen-
ent predictor of total MES number. No significant differ-nce was found in the number of patients with new
ost–carotid artery stenting embolic lesions.
In an evolving area in the field, White et al. (39) provide
review on the potential for acute percutaneous stroke
ntervention. They note acute ischemic stroke, similar to
cute MI, requires timely reperfusion. Improving outcomes
or acute stroke will require patient education for early
resentation, an aggressive expansion of qualified hospitals,
nd willing providers and early imaging strategies.
latelet Function and Antiplatelet Therapy
nderstanding of the factors influencing PR in response to
he P2Y12 inhibitor clopidogrel and its variation over time
was enhanced by Campo et al. (40). In 300 patients
undergoing PCI, they measured on-clopidogrel PR before
PCI and at 1 and 6 months after (VerifyNow assay); tested
for CYP2C19*2, *17, CYP3A5*3, and ABCB1 polymor-
hisms; and did 1-year follow-up for both ischemic and
leeding outcomes. Surprisingly, PR varied over time, with
5 of 300 patients becoming full responders. Genotyping
as able to account for only 18% of this trend. Platelet
eactivity at 1 month was the best predictor of clinical
vents. This meticulously done study, as highlighted by an
ccompanying editorial by Angiolillo (41), provides a plau-
ible explanation for the negative findings of the GRAVITAS
Gauging Responsiveness With a VerifyNow Assay–Impact
n Thrombosis and Safety) study in that assessment of PR
nd adjustment of clopidogrel dose did not modify 6-month
utcomes.
Clopidogrel requires a 2-step oxidative process mediated
y hepatic CYP enzymes for activation that might be
affected by calcium-channel blockers (CCB) that are me-
tabolized by CYP3A4. Olesen et al. (42) examined such a
possible interaction in 56,800 MI patients in Denmark
followed for 1 year. They found that CCB use was
associated with a higher event rate, most likely reflective
of increased diabetes and renal function in those treated
with CCB. This difference was similar to the increased
risk associated with CCB in the absence of clopidogrel
treatment. The investigators conclude that in this nation-
wide survey there was no evidence for a clinically signif-
icant decrease in the clinical efficacy of clopidogrel with
CCB.
Clopidogrel-drug interactions were also the subject of an
in-depth state-of-the-art paper by Bates et al. (43). The
investigators reviewed the potential for treatment with
proton-pump inhibitors (particularly omeprazole), as well as
statins to impair the platelet response to clopidogrel. In
keeping with the conclusions by Olesen et al. (42) regarding
CCB, the investigators conclude that there is inconsistent
evidence for the pharmacodynamic effect of any agent
having an impact on clinical outcomes.
Acetylsalicylic acid has been shown to decrease saphenous
vein graft thrombosis, the main mechanism for early bypass
graft loss. Gluckman et al. (44) assessed acetylsalicylic acid
d508 DeMaria et al. JACC Vol. 59, No. 5, 2012
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patients undergoing CABG. Platelet function was assessed
by platelet closure time, the VerifyNow Aspirin assay, and
urine 11-dehydro-thromboxane B2 (UTXB2). The investi-
gators found that whereas arachidonic acid–induced platelet
aggregation was inhibited in 95% and 99% of patients at 3
and 6 months, 73% had evidence of elevated UTXB2 at 3
days, with 31% still having increased levels at 6 months.
Persistent UTXB2 production as well as closure time
(indicative of shear-dependent platelet reactivity) were pre-
dictive of early saphenous vein graft thrombosis. The
elevated UTXB2 production is likely not the result of
aspirin resistance given the almost complete inhibition of
arachidonic acid–induced platelet aggregation. An accom-
panying editorial by Storey (45), underscores the need for
further evaluation of non–acetylsalicylic acid therapies for
patients undergoing CABG.
Sorensen et al. (46), using nationwide Danish registries,
examined the use and efficacy of clopidogrel in 3,545
post-CABG patients. Clopidogrel was used in only 27% of
patients, but was associated with a reduction in death or MI
over a mean follow-up of 466 days: 4.1% vs. 7.8%.
Would novel antiplatelet therapies improve the outcome
following CABG? Held et al. (47) analyzed the efficacy and
safety of ticagrelor versus clopidogrel in patients undergoing
CABG in the PLATO (Platelet Inhibition and Patient
Outcomes) trial. A total of 1,899 patients underwent
CABG, with 1,261 receiving drugs within 7 days of surgery.
They found a reduction in total (9.7% to 4.7%, p  0.01)
and CV mortality (7.9% to 4.1%; p  0.01) with ticagrelor
versus clopidogrel in the CABG subgroup in PLATO
without evidence for excess bleeding. In an accompanying
editorial, Schneider (48) examined the potential mechanism
for this reduction. Ticagrelor has greater antiplatelet effects
as well as reversible binding. The increased antiplatelet
efficacy of ticagrelor is unlikely to be the mechanism, as
there was no correlation between antiplatelet effects and CV
mortality, nor was there a difference in bleeding. The
reversibility of ticagrelor, however, may allow its redistribu-
tion to new platelets as well as activated platelets accompa-
nying blood transfusions. Ticagrelor also inhibits the uptake
of adenosine into erythrocytes, and an additional mecha-
nism for the reduced CV benefit may involve an increase in
adenosine levels in the blood.
Ticagrelor has been associated with ventricular pauses.
To evaluate this phenomenon, the PLATO trial included a
substudy (49) in which subjects had 7-day continuous
electrocardiogram (ECG) assessment at randomization and
at 1 month. As reported by Scirica et al., ventricular pauses
3 s were more frequent in patients receiving ticagrelor
versus clopidogrel (5.8% vs. 3.6%; p 0.006) and the pauses
ecreased by the 1-month follow-up (2.1% vs. 1.7%). There
was no difference in clinically reported bradycardic events,
suggesting that this phenomenon was not clinically significant.Risk Factors and Epidemiology
Cardiovascular disease has been increasing rapidly in the
developing world (50). In a “From Around the World”
report, Paradis and Chiolero (50) analyzed the incidence of
CV risk factors in 1,100 urban Indians followed over 7 years
from a mean age of 29 to 36 years. They found a significant
increase in obesity as well as central obesity, hypertension,
impaired glucose tolerance, and diabetes mellitus. These
findings have important and alarming implications for the
future of CV health.
One possible approach to improving CV health is to
adopt a Mediterranean diet. Kastorini et al. (51) performed
a meta-analysis of 50 studies (n  534,906) that examined
the link between the Mediterranean diet and the metabolic
syndrome. The investigators report that adherence with the
diet was associated with reduced risk of metabolic syn-
drome, reduced waist circumference, increased high-density
lipoprotein-cholesterol (HDL-C), decreased triglycerides,
and improved blood pressure and glucose levels, both in
epidemiological studies and clinical trials.
The Mediterranean diet is a good source of potassium.
To better determine whether potassium intake is associated
with decreased CV risk, D’Elia et al. (52) performed a
meta-analysis of 11 prospective epidemiologic studies of
247,510 subjects. A 42-mmol increase in potassium was
associated with a 21% lower risk of stroke, with a possible
reduction in coronary heart disease and total CV disease.
Berry et al. (53) examined whether a single exercise test in
middle age predicted lifetime risk for CV mortality. They
followed 11,049 men until death or age 90 years, with a
median follow-up of 25.3 years. Cardiopulmonary fitness
was significantly associated with decreased CV mortality.
The presence of CV risk factors heightened these associa-
tions. This study, though limited to men, demonstrates the
utility of a single fitness measurement at middle age to risk
stratify for lifetime CV mortality.
Even though aerobic fitness has attracted the most
attention, the influence of muscle strength as a prognostic
indicator in hypertension was examined by Aretero et al.
(54), who followed 1,506 hypertensive men for an average of
18.3 years. Both muscular strength and cardiorespiratory
fitness were measured at baseline. After adjusting for CV
fitness, hypertensive men in the upper third of muscular
strength had a lower risk of death (HR: 0.66); men with
both high muscular and aerobic strength had the lowest
mortality risk (HR: 0.49). Thus, hypertensives may benefit
from both strength training and aerobic training.
To assess whether hydrochlorothiazide, the most com-
monly prescribed antihypertensive, is efficacious, Messerli et
al. (55) performed a meta-analysis of ambulatory blood
pressure monitoring trials at both the lower (12.5 to 25 mg)
and higher doses (50 mg). They report that whereas the
50-mg hydrochlorothiazide was similar in its effects to other
agents, both the 12.5- and 25-mg doses were significantly
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(approximately one-half of that seen with the other agents).
This finding questions the appropriateness of lower-dose
hydrochlorothiazide for first-line treatment of hypertension.
Many patients have resistant hypertension, which is
persistent hypertension despite maximally tolerated treat-
ment with 3 antihypertensive agents. The Rheos system
uses electrical impulses to activate the carotid baroreflex. In
a study directed toward resistant hypertension, Bisognano et
al. (56) examined the effect of baroreflex activation therapy
on systolic blood pressure in the Rheos Pivotal trial. In the
trial, 256 resistant hypertension subjects received devices or
served as controls (2:1) for endpoints of blood pressure
response and procedural device safety. The trial did not
meet the endpoints for acute responders or procedural
safety. However, a protocol-specified ancillary analysis
showed 42% of treated patients versus 24% of control
subjects achieved systolic blood pressure of140 mm Hg at
6 months. This study yielded intriguing results, suggesting
that carotid sinus baroreflex activation could be of value in
some patients with resistant hypertension. Further trials are
likely to be undertaken.
Bisognano et al. (57) also reported on an echo substudy in
21 patients with paired data 3 and 12 months after device
activation. The investigators report reduction in mitral
A-wave velocity, left atrial (LA) dimension, and regression
of LV hypertrophy, with 18% reduction in LV mass index.
Although limited by lack of a control group, this initial
study highlights the promise of new device-based therapies
for a host of CV conditions.
Because percutaneous renal sympathetic denervation has
been found to be of benefit to patients with resistant
hypertension, Ukena et al. (58) studied whether this proce-
dure influenced the cardiorespiratory response to exercise.
In 37 patients who underwent bilateral renal denervation,
compared with 9 untreated patients, blood pressure at rest
and maximum exercise was significantly reduced by 31 and
21 mm Hg, respectively (p  0.0001), after 3 months.
either maximum heart rate nor heart rate after exercise
as changed. Thus, renal denervation reduced blood pres-
ure during exercise without affecting heart rate competence
n patients with resistant hypertension.
The relationship between decreasing sleep-time blood
ressure and CV risk reduction was studied by Hermida et
l. (59). They studied 3,344 hypertensive subjects random-
zed into those ingesting medications upon awakening or at
edtime. The date revealed a 17% reduction in CV risk for
ach 5 mm Hg decrease in sleeping systolic blood pressure
ean (p  0.001) independent of other ambulatory blood
ressure parameters. These data showed that a decrease in
sleep blood pressure was the most significant predictor of
vent-free survival. In an accompanying editorial, Gradman
60) opined that a strong case could be made that the
edtime administration of at least some portion of antihy-
ertensive regimen should become the default standard. He
cknowledged that the ideal would be to achieve the benefits tf reducing asleep blood pressure without the necessity to
erform repeated ambulatory blood pressure monitoring in
very patient.
The issue of arterial stiffness and its relationship to
itamin D was studied by Mheid et al. (61). They measured
erum 25-hydroxyvitamin D and compared it to endothelial
unction assessed by brachial artery flow-mediated dilation
nd digital reactive hyperemia index (cardiac-femoral pulse
ave velocity in radial tonometry-derived central augmen-
ation index). Vitamin D insufficiency was associated with
ncreased arterial stiffness and endothelial dysfunction in
onductance and resistant blood vessels, irrespective of
raditional risk burden. These data leave unanswered
hether therapy with vitamin D would reverse these
ndings.
tatins and Endothelial Function
ost statin trials have compared different dosages of statins
ather than comparing different low-density lipoprotein
holesterol (LDL-C) goals. Hsia et al. (62) examined a
ubgroup from the JUPITER (Justification for the Use of
tatins in Prevention: An Intervention Trial Evaluating
osuvastatin), who attained an LDL-C level 50 mg/dl in
he rosuvastatin treatment arm, compared with those in the
lacebo group and to those not achieving LDL 50 mg/dl,
nd assessed the efficacy on total mortality, CV events, and
dverse events. Out of 8,154 subjects on rosuvastatin,
pproximately one-half achieved LDL-C cholesterol levels
f 50 mg/dl. Those whose LDL-C levels were below 50
g had a significantly lower HR of 0.35 for the primary
ndpoint compared with those in the placebo group. For
hose with HDL-C levels 50 mg/dl, the HR was 0.57.
imilar findings were seen for all-cause mortality, and there
as no signal of increased rates of myopathy, cancer,
iabetes, or neuropsychiatric disorders in the group that
chieved very low LDL-C levels.
Lee et al. (63) studied the interesting question of whether
tatin therapy would be beneficial in MI patients in whom
aseline LDL-C levels were below 70 mg/dl. As compared
o patients in whom statins were not prescribed, statin
herapy reduced a composite primary endpoint including
ardiac death with an adjusted HR of 0.56 (p  0.015).
hus, statin therapy is of value following infarction even in
atients with very low baseline levels of LDL. In an
ccompanying editorial, LaRosa (64) cautioned that this
as not a randomized prospective trial, and that the level of
DL below which no further lowering reduces the risk of
ascular disease remains undefined.
To more fully characterize the risk of diabetes with
tatins, Waters et al. (65) analyzed 3 large atorvastatin
tudies: TNT (Treating to New Targets), IDEAL (In-
remental Decrease in End Points Through Aggressive
ipid Lowering), and SPARCL (Stroke Prevention by
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dictors of new onset diabetes. There was, however, no
significant increase in CV events in those who developed
new onset diabetes.
Statins may have various pleiotropic effects beyond
LDL-C lowering. Liuni et al. (66) examined the effect of
atorvastatin on endothelial function in the setting of nitrate
use, which has been associated with endothelial dysfunction
and generation of reactive oxygen species. Liuni et al.
randomized 36 male volunteers to receive continuous trans-
dermal nitroglycerin with either placebo or atorvastatin 80
mg daily. They measured endothelial function with a
enous-occlusion strain gauge plethysmography in the
etting of acetylcholine infusion with and without intra-
enous vitamin C. They found an improved acetylcholine
esponse in the presence of atorvastatin. Vitamin C
mproved the endothelial response in the setting of
itroglycerin plus placebo but had no effect in the
resence of atorvastatin. Blood pressure responses to
ublingual nitroglycerin also improved with atorvastatin.
hus, atorvastatin improved endothelial function in the
etting of nitrate treatment, and the mechanism is likely
o be a reduction in oxidative stress.
Previous studies have demonstrated an antianginal effect
ith allopurinol. To explain the antianginal effect demon-
trated for allopurinol, Rajendra et al. (67) conducted a
lacebo-controlled crossover study in 80 CAD patients with
llopurinol 600 mg daily. They assessed endothelial dys-
unction with forearm venous occlusion plethysmography,
ow-mediated dilation, and pulse wave analysis. Infusion of
cetylcholine and vitamin C were used to assess oxidative
tress. They were able to demonstrate significantly improved
ascular function, and allopurinol abolished vascular oxida-
ive stress. Any long-term morbidity and mortality benefit
emain to be determined.
Although epidemiologic data has consistently shown that
iminished HDL-C is a potent risk factor for CV events
ven in the presence of low LDL-C levels, data on the
tility of raising HDL, particularly during concomitant
tatin therapy, is inconclusive. One novel approach has been
o increase levels of apolipoprotein A-I, the carrier protein
f HDL. In 2010, Bailey et al. (68) reported positive results
f an oral drug, RVX-208, that induces nuclear transport
actors that increase hepatic and intestinal apolipoprotein
-I production in both monkeys and humans (for a short
erm). A follow-up study by Nicholls et al. (69), however,
emonstrated only an 8.3% increase in HDL-C and 5.6% in
polipoprotein A-I and was accompanied by a 10% inci-
ence of transaminase elevations. This trial demonstrates
et again the challenges of HDL-targeted therapies for
therosclerosis (70).
cute Coronary Syndromes
ilvain et al. (71) examined thrombi obtained by throm-
oaspiration from 45 of 288 STEMI patients who under-went primary PCI. They tested for plasma biomarkers
associated with thrombosis and analyzed the composition of
the thrombi using high-definition scanning electron micros-
copy. They found that clots were composed, in descending
order, of fibrin, platelets, erythrocytes, cholesterol crystals,
and leukocytes. Longer ischemic time was associated with
an increase in fibrin content and a decrease in platelet
content. These findings have implications for fibrinolysis
and provide an explanation for the greater efficacy of lytic
therapy early in the time course of a STEMI.
Whereas plaque rupture and thrombosis have become the
main focuses of research in CAD, alternative pathophysio-
logic processes may also play a role. Ong et al. (72) in the
CASPAR (Coronary Artery Spasm as a Frequent Cause for
Acute Coronary Syndrome) study (2008) showed that no
culprit lesion was found in about one-third of ACS patients
undergoing emergency angiography. This year, they re-
ported on the 3-year follow-up of the 76 patients with only
spasm as an explanation for their ACS (73). Persistent
angina was reported by 36 of 76 of the spasm patients, but
there were no cardiac deaths or nonfatal MIs during the
follow-up. In comparison, 30 of 270 patients with culprit
lesions died during the 3-year follow-up, with 11 nonfatal
MIs. This highlights that the differing underlying patho-
physiologic causes of ACS have differing prognostic and
therapeutic implications.
Achieving rapid door-to-balloon times may be particu-
larly challenging in a rural setting. Blankenship et al. (74)
report on implementation of a rapid triage and transfer
protocol in which the rural hospital directly contacted the
accepting cardiology service with direct helicopter transfer
to the catheterization lab, bypassing the accepting hos-
pital’s emergency room. They report that median door-
to-balloon time decreased from 189 min to 88 min and
was associated with a halving of the hospital mortality
from a baseline of 6%.
The ability of nonlipid biomarkers to prognosticate CV
events in patients with stable coronary disease was assessed
by Arsenault et al. (75) for the TNT Study Investigators.
They evaluated 18 nonlipid biomarkers 8 weeks after
starting lipid-lowering therapy with atorvastatin. They ob-
served that LDL-C and HDL-C in triglycerides were
predictive of recurrent major CV events. However, many of
the nonlipid biomarkers were not predictive of recurrent
events at 8 weeks or 1 year.
From a therapeutic perspective, lowering the triglycerides–
HDL-C ratio was associated with the beneficial impact of
pioglitazone on the progression of coronary atherosclerosis
in diabetic patients in the PERISCOPE (Pioglitazone
Effect on Regression of Intravascular Sonographic Coronary
Obstruction Prospective Evaluation) study (76). In this
study, multivariate analysis revealed that pioglitazone-
induced effects on triglycerides to HDL-C were associated
with changes in percentage of atheroma volume (p  0.03).
These findings emphasized the importance of atherogenic
dyslipidemia in diabetic patients.
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conducted a meta-analysis to determine the effect of erectile
dysfunction. Drawing from 12 prospective cohort studies
involving over 36,000 patients, they observed a relative risk
for CV disease of 1.48 in men with erectile dysfunction.
Similar results were obtained when analyzing studies with
control groups for conventional risk factors, suggesting that
the increased risk associated with erectile dysfunction is
probably independent of these factors.
Several niche issues were evaluated in patients with acute
MI. The CONNECT (Clinical Evaluation of Remote
Notification to Reduce Time to Clinical Decision) trial by
Crossley et al. (78) evaluated the ability of wireless remote
monitoring with automatic clinician alerts to decrease the
time from the onset of a clinical event to the reaching of a
clinical decision. The technology used the ability of im-
plantable cardioverter-defibrillators to detect and wirelessly
transmit diagnostics regarding individual patients. Just un-
der 2,000 patients were monitored for 15 months for
CV-related hospitalizations, emergency department visits,
and clinic office visits. The median time from clinical event
to clinical decision in patients who underwent monitoring
was less than those treated in a conventional fashion, as was
the hospital length of stay. Thus, these data suggest that
beneficial clinical decision making can be markedly acceler-
ated by remote notification.
Finally, Kar et al. (79) assessed the safety and effectiveness
of a percutaneous ventricular assist device in patients with
refractory cardiogenic shock despite intra-aortic balloon
counterpulsation. They implanted the TandemHeart assist
device (CardiacAssist, Pittsburgh, Pennsylvania) in 117
patients for an average of 5.8 days in both ischemic and
nonischemic cardiomyopathy. The percutaneous assist
device markedly improved systolic blood pressure, mixed
venous oxygen saturation and urine output, and resulted
in 30-day and 6-month mortalities of 40.2% and 45.3%,
respectively. Thus, the percutaneous ventricular device
appears to be of value in patients with refractory cardio-
genic shock. In an accompanying editorial, Tallaj and
Cadeiras (80) commented that the TandemHeart could
be implanted relatively quickly, was associated with a low
complication rate, and rapidly restored circulatory sup-
port. However, they cautioned that neither the patients
who could benefit from this therapy nor the cost-
effectiveness was certain.
Heart Failure
There is a need for information relating how health care is
funded with regard to quality and outcomes. Kapoor et al.
(81) analyzed the relationship between payment source and
quality of care and outcomes in 99,508 HF admissions from
244 sites participating in the GWTG (Get With the
Guidelines) program between January 2005 and September
2009. Patients were categorized according to payer status
(private/health maintenance organization, no insurance,Medicare, or Medicaid) using private/health maintenance
organization as the reference group. They found that the
no-insurance group was less likely to receive evidence-based
beta-blockers, implantable cardioverter-defibrillators, or an-
ticoagulation for AF, and the Medicaid group was less likely
to receive evidence-based beta-blockers or implantable
cardioverter-defibrillators. Angiotensin-converting enzyme
inhibitors or angiotensin receptor blockers and beta-
blockers were prescribed less frequently in the Medicare
group. Overall, Medicare, Medicaid, and no-insurance
groups had longer hospital stays, and there were higher
in-hospital mortality rates in Medicaid and in uninsured
patients with reduced systolic function. These results
suggest that quality of care and outcomes of patients
admitted for HF is influenced by payer source. In an
accompanying editorial, Konstam (82) commented that
this analysis offered potentially important information
about the impact of future models of funding. He
suggests that consideration be given to bundling pay-
ments for patient populations and allowing providers to
manage their overall costs by improving efficiency and
eliminating unnecessary utilization, and to offering pa-
tients financial incentives, allowing them to share in the
global payment in return for keeping appointments and
adhering to dietary and medication prescriptions.
Although diuretics are the main treatment for congestion
in HF patients, there are concerns about their effects on
kidney function. Damman et al. (83) studied the pharma-
codynamic effect of withdrawal and reinstitution of diuretics
on markers of renal and tubular function. In 30 euvolemic
patients with systolic dysfunction receiving standard furo-
semide therapy, withdrawal of the diuretic for 72 h resulted
in increases in atrial and B-type natriuretic peptides.
Whereas serum creatinine was unaffected, both urinary
kidney injury molecule-1 and urinary N-acetyl-beta-D-
glucosaminidase concentrations, but not serum or urinary
neutrophil gelatinase-associated lipocalin, rose significantly
after diuretic withdrawal. After reinitiation of furosemide,
both urinary injury molecule-1 and N-acetyl-beta-D-
glucosaminidase concentrations returned to baseline. These
findings support the concept that diuretic withdrawal and
reinstitution can increase and decrease markers of tubular
dysfunction in stable HF, suggesting that diuretic therapy
may favorably affect renal and tubular function by decreasing
congestion. As noted by Gottlieb (84) in the accompanying
editorial, there is still much to be learned about diuretics and
our current views of diuretic actions may need to be
modified in the future.
There is evidence that dependent edema and overnight
rostral fluid shift from the legs correlates with the severity of
sleep apnea in HF patients. Recognizing that excessive
sodium intake can cause fluid retention, Kasai et al. (85)
assessed whether the severity of sleep apnea is related to
sodium intake in HF patients. They determined the amount
of sodium intake in 54 HF patients who underwent over-
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and correlated with the apnea-hypopnea index. These find-
ings suggest the possibility that sodium intake plays a role in
the pathogenesis of sleep apnea.
The HeartMate (HM) II (Thoratec, Pleasanton, Califor-
nia), approved by the Food and Drug Administration, is a
continuous flow device for bridge to transplant or destina-
tion therapy that was required to demonstrate comparable
results to available devices. Starling et al. (86) reported
results from the INTERMACS (Interagency Registry for
Mechanically Assisted Circulatory Support) in which 169
consecutive patients treated with the HM II LV assist
device were compared for outcomes with patients treated
with other devices. The adverse event rate was similar or
lower for HM II. Operative 30-day mortality for HM II
was 4% versus 11% for the comparison group. The
percentage of patients reaching transplant, cardiac recov-
ery, or ongoing LV assist device support by 6 months was
91% for HM II and 80% for other devices, and the
Kaplan-Meier survival for patients remaining on support
at 1 year was 85% for HM II versus 70% for the other
devices. These findings confirm that use of the HM II
outside of clinical trial settings is associated with highly
beneficial clinical results.
The HeartWare Ventricular Assist Device (HeartWare
International, Framingham, Massachusetts) is a new me-
chanical circulatory support system that is smaller and more
durable than previous LV assist device systems and can be
placed within the pericardial space, thereby avoiding the
need for abdominal surgery. Strueber et al. (87) reported
the initial clinical evaluation of the HeartWare Ventric-
ular Assist Device in a multicenter, prospective, nonran-
domized single-arm clinical trial in which 50 heart trans-
plant candidates with NYHA functional class IV symptoms
were supported until heart transplant, myocardial recovery
and device explant, or death. Of the 50 patients, 20 received
transplants, 4 had the pump explanted after myocardial
recovery, and 17 continued support at 2 years. Nine patients
died during support from sepsis (n  3), multiple organ
ailure (n  3), or hemorrhagic stroke (n  3). The actual
urvival at 6, 12, and 24 months was 90%, 84%, and 79%,
espectively. In the survivors, measures of quality of life
howed a significant improvement over baseline values,
nd there were significant improvements for recognition
emory at 3 months after implant. These results dem-
nstrate that patients with end-stage HF can be safely
nd effectively supported by the HeartWare Ventricular
ssist Device system with improved quality of life and
eurocognitive function. In an accompanying editorial,
amboukian (88) noted the progress that has been made
s ventricular assist devices have evolved over the past
everal years. He defined 6 major hurdles that have
imited the widespread application of the technology: 1)
evice size; 2) device durability; 3) survival; 4) drivelinenfections; 5) thrombotic and bleeding complications;nd 6) awareness of the benefits of this technology in the
reater cardiology community.
Heart failure with preserved ejection fraction (HFpEF) is
resent in approximately one-half the cases of HF.
aykowsky et al. (89) investigated the mechanisms respon-
ible for reduced aerobic capacity (peak Vo2) in HFpEF
patients. They found that reduced peak Vo2 in HFpEF
patients was associated with a reduced peak cardiac output
and arterial-venous O2 (A-Vo2) difference. The strongest
independent predictor of peak Vo2 was the change in A-Vo2
difference from rest to peak exercise (A-Vo2 difference
eserve) for both HFpEF patients and controls. Because
-Vo2 difference reserve is an independent predictor of
peak Vo2, these findings also support the concept that
peripheral, noncardiac factors are important contributors to
exercise intolerance in these patients. In an accompanying
editorial, Maurer and Hummel (90) comment that this
report emphasizes the role of peripheral mechanisms rather
than the more traditional view of abnormalities in diastolic
function.
Although HFpEF patients have impaired exercise capac-
ity, the effects of exercise training are uncertain. Edelmann
et al. (91) sought to determine whether structured exercise
training improves maximal exercise capacity, LV diastolic
function, and quality of life in HFpEF patients. In this first
multicenter trial of exercise in HFpEF patients, they ran-
domized 64 patients to supervised endurance/resistance
training in addition to usual care or to usual care alone. Peak
Vo2, the primary endpoint, significantly increased with
exercise training but not with usual care, with a mean
benefit of 3.3 ml/min/kg. E/e’ and LA volume index
decreased with exercise training and remained unchanged
with usual care. These results demonstrate a beneficial effect
of exercise training in HFpEF patients. In an accompanying
editorial, Kitzman (92) noted that the changes demon-
strated in HFpEF patients were of similar magnitude to
those reported with systolic dysfunction, and that they
clearly exceeded the threshold for a clinical meaningful
change in exercise capacity.
Treatment of HFpEF remains problematic because the
results of large-scale clinical trials have been negative.
Holland et al. (93) performed a meta-analysis of trials in
HFpEF patients and found that pharmacotherapy dem-
onstrated a quantifiable improvement in exercise toler-
ance but not in measures of diastolic function or in
mortality. Given the advanced age of HFpEF patients
compared with systolic dysfunction patients, improve-
ment in outcomes such as exercise tolerance might be
more achievable and pragmatic.
There is increasing appreciation that multiple factors can
contribute to the HFpEF phenotype. Kasner et al. (94)
investigated the relationship of changes in myocardial col-
lagen using echo-Doppler assessment of diastolic function
in a cohort of HFpEF patients. Overall, 26 (of 41) HFpEF
patients showed a significant increase in total collagen and
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with that of 15 control subjects. Among all Doppler flow
variables, only E deceleration time was associated with the
collagen volume fraction from heart biopsy specimens,
whereas Doppler tissue parameters correlated with collagen
volume fraction, collagen I at the protein and messenger
ribonucleic acid levels, and LV filling index. Collagen
overexpression correlated with reduced exercise capacity.
The findings support a causal association between changes
in myocardial collagen and abnormal diastolic function in
HFpEF patients and raise the possibility that altering
collagen production could benefit patients with this condi-
tion.
Two papers published this year dealt with the effect of
obesity on cardiac function. Owan et al. (95) evaluated the
effect of gastric bypass surgery on cardiac remodeling and
function. Compared with a reference group, gastric bypass
in 423 severely obese patients resulted in a substantial
decrease in BMI (15.4 kg/m2). The bypass group had
ecreased LV mass index, right ventricular cavity area,
ncreased mid-wall fractional shortening, and right ventric-
lar fractional area change. These data provide support for
he application of gastric bypass surgery in patients with
orbid obesity.
Russo et al. (96) evaluated the effect of excess weight and
besity on LV diastolic function. They divided 950 subjects
nto normal weight, overweight, and obese (BMI 30
g/m2) categories. In multivariable analysis, BMI was inde-
pendently associated with an increased E/E= radio. Over-
weight and obese had lower E= velocities and higher E/E=
ratios (both p  0.01). Compared to normal weight
ubjects, the risk of diastolic dysfunction in overweight
ubjects was 1.52 and in obese subjects 1.60. The abnor-
alities of diastolic dysfunction observed in overweight and
bese individuals in this study may partially explain the
ncreased risk of HF in these individuals.
lectrophysiology
n the RACE II (Rate Control Efficacy in Permanent Atrial
ibrillation II) study (97), Smit et al. reported data from a
andomized comparison of strict (80 beats/min) versus
enient (80 to 110 beats/min) ventricular rate control in
atients with permanent AF. No independent effect of rate
n LA size or volume or LV end-diastolic diameter was
bserved in 256 patients randomized to strict versus 261 to
enient rate control, but female sex adversely affected LA
ize and LV end-diastolic diameter. The findings support a
ore liberal effort to control ventricular rate, as compared
ith the AFFIRM (Atrial Fibrillation Follow-Up Investi-
ation of Rhythm Management) and original RACE stud-
es. Wyse, in an editorial comment on this paper (98),
oints out several issues with this study that may limit its
linical applicability. First, the difference in average heart
ate achieved over the 3-year duration in the strict arm was
mall (approximately 85 beats/min vs. 75 beats/min), but ihe mean heart rate was 100 beats/min in both groups.
he AFFIRM and original RACE study showed adverse
ffects of heart rates 100 beats/min. Second, Wyse notes
hat to overcome the modest study size the composite
ndpoint included at least 8 components, including bleeding
isk, which is not likely to be affected by rate control. Wyse
lso notes a trend for decreases in LA and LV size in the
trict rate control group that may not have been statistically
ignificant due to the relatively small size of the study. In
ddition, the time course of remodeling of the human LA is
nknown, and it is not clear what effect this may have had
n the study outcomes. Lastly, there were only a modest
umber of baseline variables included in the statistical
odel in this study and other unknown variables could have
otentially negated the finding with respect to gender effect
n this study. For these reasons, it may be best to consider
ACE II a stimulus for further research on this subject,
ather than proof that more lenient rate control is without
isk in patients with persistent AF.
In the MADIT-CRT (Multicenter Automatic Defibril-
ator Implantation Trial with Cardiac Resynchronization
herapy) study, Goldenberg et al. (99) reported data on
,820 patients, randomized in a 3:2 ratio to cardiac resyn-
hronization therapy with defibrillator (CRT-D) versus
efibrillator therapy only, who were followed for 4.5 years.
nclusion required ischemic cardiomyopathy with NYHA
lass I or II, or nonischemic cardiomyopathy with class II
nly, sinus rhythm, LVEF 30%, and QRS duration 130
s. CRT-D significantly reduced risk of first (HR: 0.54,
 0001) and subsequent HF events (HR: 0.62, p 
.003) compared with implantable cardioverter-defibrillator
ICD) therapy alone, most prominently in patients with left
undle branch block at enrollment (HR: 0.38, p  0.001)
ith no effect without left bundle branch block. The
ccurrences of the first and second HF events were associ-
ted with 7- and nearly 19-fold increased risk of subsequent
ortality. There was some crossover between study arms,
ut this was nearly equal between groups, and most of the
rossover from CRT-D to ICD only was before a first HF
vent. This study showed for the first time that CRT was
ssociated with a reduction in the risk of recurrent HF
pisodes and confirms that recurrence of HF events is
ssociated with a marked worsening of prognosis.
In a MADIT-CRT substudy, Barsheshet et al. (100)
ompared the risk of first ICD therapy for ventricular
achyarrhythmia (VTA) between high- and low-echo re-
ponders to CRT-D therapy (defined as 25% and 25%
eduction in LV end-systolic volume at 1 year) and ICD-
nly patients. The risk of VTA at 2 years after assessing
chocardiographic response was highest among low re-
ponders to CRT-D (28%), intermediate among ICD-only
atients (21%), and lowest among high responders to
RT-D (12%), with p  0.001 among the groups during
ollow-up. There was a 55% reduction in VTA in high
esponders to CRT-D, with no significant difference in risk
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of subsequent VTA. These findings suggest that reverse
remodeling during CRT-D is associated with a significant
risk reduction of life-threatening VTA, and that early
resynchronization with CRT-D in ischemic and nonisch-
emic cardiomyopathy patients with reduced ventricular
function may benefit those who respond to therapy. In an
editorial, Curtis (101) comments that there appears to be a
slightly increased risk of VTA (a possible proarrhythmic
effect) in patients who do not respond to CRT-D with
reverse remodeling, and it may be important to avoid such
therapy in those patients. Perhaps one should consider
turning off CRT and rely only on the ICD function in those
without ventricular remodeling after initial implantation.
Eckart et al. (102), in a study of sudden death in young
adults, evaluated demographic and autopsy data from the
Department of Defense Cardiovascular Death Registry over
a 10-year period, comprising 15.2 million person-years of
active surveillance. The investigators identified 902 subjects,
mean age 38  11 years, in whom the cause of death was
adjudicated as potentially cardiac in etiology. The mortality
rate for sudden cardiac death (SCD) was 6.7 per 100,000 in
men and 1.4 per 100,000 in women (p  0.001) and was
attributable to a cardiac condition in 715 (79.3%). The
incidence of unexplained sudden death was 1.2 per 100,000
in those35 years of age, and 2.0 per 100,000 in those35
years of age, with the incidence of atherosclerotic coronary
artery disease 0.7 per 100,000 in those35 years of age, and
13.7 per 100,000 in those 35 years of age (p  0.001).
he investigators concluded that prevention of sudden
eath should focus on evaluation for primary arrhythmia in
hose 35 years of age, with an emphasis on evaluation for
AD in those 35 years of age.
Greenspon et al. (103) reported on a trend in infection
urden in cardiac implantable electrophysiological devices
CIED) in the United States from 1993 to 2008. The
ationwide Inpatient Sample discharge records were que-
ied, with CIED infection defined as either an ICD-9
International Classification of Diseases-9th Revision) code
or device infection (996.61) and any CIED procedure or
emoval code, or a CIED procedure code along with
ystemic infection. In addition, patient comorbidity codes
or renal, heart, or respiratory failure or diabetes were
valuated. The investigators found a 4.7% annual increase in
IED implantation during the study period, primarily due
o ICD implantation (504% increase in ICD versus 45% in
acemaker implantation). The average incidence of CIED
nfection was 1.61%, which remained constant until 2004
hen there was a marked increase coinciding with an
ncrease in major comorbidities. This was associated with a
arked increase in mortality (1% per decade) and in-
ospital financial charges (an increase of 47% per decade).
hus, the absolute number of CIED implantations (partic-
larly ICDs) significantly increased over the past 2 decades,
nd this is associated with a significantly greater risk of
nfectious complications and dramatic cost increases.Gollob et al. (104) proposed diagnostic criteria for the
short QT syndrome (SQTS), a relatively newly described
cardiac channelopathy associated with AF and SCD. In
some cases, the cause of the SQTS has been identified as a
mutation in the KCNH2 gene resulting in up-regulation of
the IKr or HERG potassium channel, which accelerates
action potential repolarization. Mutations in the KCNQ1
gene, resulting in functional up-regulation of the IKs chan-
nel have been identified in other cases, as have those in the
KCNJ2 gene resulting in functional up-regulation of the
IK1 gene. The wide overlapping range of QT intervals
between cases and healthy subjects, with no arrhythmias
occurring in populations with QT intervals equally short or
shorter than some cases with sudden death due to ventric-
ular arrhythmias, has made the definition of the syndrome
difficult. The investigators identified 61 reported SQTS
cases in the English language MEDLINE database, and
presentation, sex, ECG criteria including QT interval,
genetic analysis when available, and family history. From
this data, the investigators proposed diagnostic criteria for
SQTS, with major emphasis on QT interval and J-point to
T-peak interval, also including history of cardiac arrest,
polymorphic ventricular tachycardia or ventricular fibrilla-
tion, unexplained syncope, AF, family history in first- or
second-degree relatives of SQTS or unexplained sudden
death, or sudden infant death syndrome, and genotype.
They then assigned a point score to each of the diagnostic
criteria. The proposed criteria may not be agreed on by all,
but this paper represents a first step toward identifying
patients with this rare but lethal genetic syndrome.
Giustetto et al. (105) described the long-term outcome of
patients with SQTS, a rare channelopathy that has also
recently been associated with sudden cardiac arrest (SCA).
The investigators identified 53 patients from the European
Short QT Registry (75% men; median age: 26 years) who
were followed for 64  27 months. Eighty-nine percent of
individuals had a familial or personal history of SCA, with
32% presenting with SCA. The average QT interval cor-
rected for heart rate (QTc) in the population was 314  23
ms. A defined mutation was found in 23% of probands,
most having a gain of function mutation in HERG
(SQTS1). Twenty-four patients received an ICD, and 12
patients received hydroquinidine. During follow-up, the
event rate was 4.9% per year in the patients without
antiarrhythmic therapy. No arrhythmic events occurred in
patients receiving hydroquinidine. The investigators con-
cluded that SQTS carries a high risk of SCA in all age
groups, that symptomatic patients had a high risk of
recurrent arrhythmic events, and that hydroquinidine was
effective in preventing arrhythmic events follow-up.
Treatment for Atrial Fibrillation
There is growing awareness of the epidemic of AF (106–108).
In a Viewpoint, Mittal et al. (107) discuss how rigorous
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cryptogenic stroke and will likely intensify our monitoring
and therapy goals for AF patients in the future. Several
studies this year focused on the therapy, management, and
underlying mechanisms of AF.
Saksena et al. (109) reported an important substudy from
AFFIRM (Atrial Fibrillation Follow-Up Investigation of
Rhythm Management trial) that examined CV outcomes
based on specific antiarrhythmic medication in 1,603 pa-
tients initially receiving amiodarone (45%), sotalol (38%),
and flecainide or propafenone (17%). Using propensity
scores to match antiarrhythmic groups, the investigators
showed that the composite endpoint of mortality or cardio-
vascular hospital stay (CVH) was worse for amiodarone or
sotalol (p  0.02 or p  0.001, respectively) than rate
control was. Amiodarone also conferred a higher risk of
non-CV death (HR: 1.11, p  0.04), higher CVH event
rates at 3 years, and shorter time to CVH with intensive care
unit stay or death (HR: 1.22, p  0.03). There were no
significant differences in overall survival between antiar-
rhythmic medication groups and matched rate control
subjects. The investigators concluded that CVH event rates
during follow-up were high for all cohorts, but were higher
for all groups receiving antiarrhythmic medications. The
editorial commentary by Markowitz (110) points out that
clinical differences may still contribute to these data (for
instance, some coronary disease patients received class I
agents) and emphasizes that antiarrhythmic medications
have been shown to improve outcomes in some trials.
Disappointment with antiarrhythmic medications for AF
continues to fuel interest in nonpharmacological therapy to
restore sinus rhythm. Several studies in the Journal in 2011
examined outcomes from percutaneous AF ablation. Gertz
et al. (111) examined the impact of successful ablation of AF
on MR. Out of 828 patients undergoing first AF ablation,
they retrospectively compared 53 with at least moderate MR
to 53 with mild or undetectable MR. The investigators
found that patients in sinus rhythm on follow-up had less
MR and greater reduction in LA size on echocardiograms,
than those not in sinus rhythm. They conclude that these
data support the concept of atrial functional MR, in
contradistinction to functional MR from ventricular dila-
tion. In an accompanying editorial, Hoit (112) writes that
these provocative data may be the first to show a cause-effect
relationship between LA enlargement and functional MR.
Although clinical stroke or transient ischemic attack is an
uncommon complication of AF ablation (1%) (113),
Herrera Siklo´dy et al. (114) compared silent cerebral emboli
using 3 competing ablation catheters: a conventional irri-
gated catheter; a cryoballoon; and a new multielectrode
phased pulmonary vein ablation catheter (PVAC). The
investigators performed cerebral MRI in 74 patients 1 day
before and within 2 days after pulmonary vein isolation,
ensuring strict periprocedural anticoagulation. The investi-
gators report that post-procedure MRI detected a single
new embolic lesion in 2 of 27 patients of the irrigated ficatheter group (7.4%), 1 of 23 patients of the cryoballoon
group (4.3%), and 9 of 24 of the PVAC group (37.5%),
demonstrating 2.7  1.3 new lesions (range 1 to 5; median:
3; p  0.003). Clinical examination (not performed by
eurologists) was normal in all patients after ablation. The
nvestigators conclude that the PVAC catheter is associated
ith a higher incidence of subclinical intracranial embolic
vents. Similar data were also recently reported elsewhere in
parallel study (115). An accompanying editorial (116)
iscusses these issues in detail. Of note, the U.S. Food and
rug Administration recently decided against approval of
he novel PVAC catheter (117) citing safety concerns
ncluding these data. On this topic, a separate report from
he Taipei group in 2011 suggests that the CHADS2-VASc
core may identify risk of thromboembolism after catheter
blation for AF better than the CHADS2 score (118).
As catheter ablation for AF continues to grow in utiliza-
ion, it is increasingly important to fully understand the
ong-term results following this procedure. Weerasooriya et
l. (119) systematically followed 100 patients for 5 years
fter a single initial catheter ablation procedure. They
ocument steady erosion in the arrhythmia-free survival
ith only 29% of patients free of recurrence at 5 years. This
ealistic assessment of long-term success rates provides the
V community with useful insights into the natural history
f AF following ablation.
The field of surgical, nonpercutaneous ablation for AF
lso continues to grow. An interesting study by Onorati et
l. (120) evaluated the impact of different surgical lesions for
F ablation in 141 patients followed prospectively after
itral valve and maze surgery. Patients received either a
limited” LA radiofrequency lesion set in 32 patients or an
extensive” set in 109 patients that combined left and right
trial lesions with ganglionic plexus isolation in some cases.
he investigators found the post-procedural prevalence of
F to be lower in patients receiving extensive versus limited
blation (adjusted RR: 0.10; p  0.001) at discharge, 3
onths after, and 18 months after. This was associated with
ewer patients in NYHA class II/III, lower rates of hospi-
alization and of the combined endpoint of death/
ospitalization over time, and lower usage of antiarrhythmic
rugs in the extensive ablation arm. The investigators
oncluded that adding right-sided lesions improved results
rom the surgical maze procedure. These data support the
eport by Hocini et al. (121), who reported that percutane-
us ablation in the right atrium was required for optimal
esults in some patients.
Several studies dealt with issues related to AF. Melduni et
l. (122) examined the relationship between new-onset
ost-operative AF within 30 days of surgery and evidence of
V diastolic dysfunction. Post-operative AF was observed
n 38.5% of 351 patients. Left ventricular diastolic dysfunc-
ion was an independent predictor with an odds ratio (OR)
f 5.12 (p 0.006). Thus, LV diastolic dysfunction appears
o be a pre-disposing substrate for post-operative AF and a
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patients was studied in the ATRIA (Anticoagulation of
Risk Factors in Atrial Fibrillation) study. Fang et al. (123)
examined the follow-up of 9,186 AF patients to derive a risk
score for the likelihood of hemorrhage. Five independent
variables were included in the final model: anemia
(3 points); severe renal disease (3 points); age greater than
75 years (2 points); prior bleeding (1 point); and hyperten-
sion (1 point). Major hemorrhage rates ranged from 0.4%
with 0 points to 17.3% per year with 10 points. Thus, this
risk score applying easily obtainable parameters affectively
quantified the risk of warfarin-associated hemorrhage in
patients with AF.
Mechanisms of Human Atrial Fibrillation
Several studies in the Journal this year shed light on the
sustaining mechanisms for human AF. The 2 prevailing
hypotheses are, first, that AF is caused by spatially mean-
dering electrical waves (the multiwavelet hypothesis (124))
and, second, that AF is caused by electrical spiral waves
(rotors) or focal beat sources from which activity disorga-
nizes to the surrounding atrium (the localized source hy-
pothesis (125)). Chou et al. (126) provided data to support
the localized source hypothesis, in Langendorff-perfused
LA-pulmonary vein preparations from 13 dogs. Sustained
AF was induced by rapid pacing and acetylcholine infusion
and was characterized by rotors in all animals with addi-
tional focal beat sources in just over one-half. Epicardial
ablation of rotor sites suppressed subsequent AF initiation
and shortened the duration of induced AF. Notably, AF was
suppressed even in animals in which the pulmonary veins
continued to exhibit triggering ectopy. Preliminary human
data recently showed that percutaneous ablation of AF
rotors and focal beat sources can provide acute termination
and long-term elimination of AF (127).
The mechanisms for re-entrant circuits in AF are often
attributed to electrical and structural remodeling (128) that
in turn is often attributed to atrial fibrosis and age. Platonov
et al. (129) reported unique histologic analyses of autopsies
from 30 consecutive patients without a documented history
of AF, or with paroxysmal AF or permanent AF. Remark-
ably, the investigators found no correlation between age and
fibrosis at any atrial location. Conversely, the extent of
fibrosis and fatty infiltration were 2- to 3-fold higher in
patients with AF, particularly permanent AF. The editorial
commentary by Asirvatham and Gard (130) questions
whether these data are sufficient to overturn conventional
wisdom linking atrial fibrosis with aging.
In a separate report examining electrical remodeling, Tsai
et al. (131) studied cultured atrial myocyte monolayers
exposed to stretch, a known precipitant of AF. The inves-
tigators found that stretch caused oscillations in cellular
calcium and repolarization, which are known to predispose
to AF. These data also agree with a recent human report in
which repolarization oscillations were most likely in patients fwith remodeled atria and indicated imminent AF onset
(132). Tsai et al. (131) found that overexpression of sarco-
plasmic reticular adenosine triphosphatase reversed cellular
abnormalities in their preparation, suggesting a novel ther-
apeutic avenue for AF.
Clinical Syndromes
That Elevate Sudden Death Risk
It remains extremely difficult to identify individuals at risk
for SCA from VTA (133). Despite the emphasis of risk
stratification schemes on LV dysfunction, most cases of
SCA occur in individuals with preserved ejection fraction.
Several studies in the Journal in 2011 focused on early
repolarization syndrome (ERS), a recently reported cause of
SCA in individuals with structurally normal hearts. Derval
et al. (134) examined the prevalence of ERS in the
CASPER (Cardiac Arrest Survivors with Preserved Ejec-
tion Fraction Registry), of whom 100 patients (40 women,
age 43  14 years) underwent extensive clinical and genetic
esting and blinded independent ECG analysis. Early repo-
arization was defined as 0.1 mV J-point elevation in 2 or
ore contiguous inferior and/or lateral leads. Forty-four
atients had an established cause for cardiac arrest, with
arly repolarization in 19 patients, including 6 with a
rimary diagnosis that explained their cardiac arrest (14%),
ompared with 23% of the 56 patients with idiopathic
entricular fibrillation (p  0.23). J-point elevation in IVF
atients had higher amplitude (0.25  0.11 mV vs. 0.13 
.05 mV; p  0.02) and wider distribution (4.3  1.3 leads
s. 2.8  0.8 leads; p  0.01) than in patients with
stablished causes for cardiac arrest. Notably, J-wave ampli-
ude was labile on serial ECGs. The investigators concluded
hat early repolarization is present in both etiology-
dentified as well as idiopathic ventricular fibrillation.
In a separate report, Nunn et al. (135) hypothesized that
RS is inherited and may be responsible for some cases of
udden arrhythmic death syndrome. In 363 first-degree
elatives from 144 families of sudden arrhythmic death
yndrome probands, the investigators found that J-point
levation (0.1 mV from baseline in 2 or more inferior or
ateral leads) was higher than in 359 matched controls (23%
s. 11%; OR: 2.54; p 0.001). The investigators concluded
hat ERS is a potentially inheritable marker of proarrhyth-
ia in sudden arrhythmic death syndrome. In a separate
eport examining 3,955 participants in the Framingham
eart Study and 5,489 participants in the Health 2000
urvey, Noseworthy et al. (136) found ECG evidence of
arly repolarization in 6.1% and 3.3% of their cohorts,
espectively. In the Framingham cohort, siblings of individ-
als with early repolarization had this pattern in 11.6% of
ases, for an elevated unadjusted OR of 2.22 (p  0.047).
he investigators concluded that the ECG pattern of early
epolarization is inherited, but they did not examine clinical
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are labile. Goldenberg et al. (137) examined the natural
history of patients with “genotype-confirmed LQTS” yet
normal QTc intervals. The investigators studied 3,386
genotyped subjects from the United States, Western Eu-
rope, and Japan in whom they examined clinical and genetic
risk factors for aborted cardiac arrest (ACA) or SCA from
birth through age 40 years. The investigators found that
although the probability of ACA or SCD in patients with
long QT syndrome (LQTS) with normal-range QTc (4%)
was lower than in those patients with prolonged QTc (15%)
(p  0.001), it was higher than in unaffected family
members (0.4%) (p 0.001). Risk factors for ACA or SCD
in patients with normal-range QTc included the specific
mutation and LQTS genotype, but clinical factors were
associated with increased risk only in patients with pro-
longed QTc. The investigators concluded that genotype-
confirmed patients with concealed LQTS constitute 25% of
the at-risk LQTS population, and that genetic data identify
increased risk for ACA or SCD in this overall lower-risk
subgroup. This provocative report opens up the potentially
enormous field of investigating and treating patients with
genetic abnormalities yet no clinical abnormality, as dis-
cussed in an accompanying editorial by Roden (138).
Several approaches are being taken with novel pharma-
cological therapies for arrhythmic syndromes. Den Ruijter
(139) studied rabbit cardiomyocytes in vitro and found that
superfusion with reconstituted HDL (to simulated elevated
HDL-C) shortened ventricular action potential duration. In
a pilot clinical study by the investigators, reconstituted
HDL infusion in dyslipidemic and control subjects caused a
shortening in QTc on the ECG in all subjects. The
investigators concluded that shortening of repolarization by
reconstituted HDL might explain the salutary effects of
HDL, lipid management, and statins on reducing sudden
death. Clearly, these data need validation in a larger cohort.
In a separate report, Fabritz et al. (140) tested whether a
reduction of vascular volume prevented the arrhythmogenic
phenotype in a murine model of arrhythmogenic cardiomy-
opathy (ARVC). In heterozygous plakoglobin-deficient
mice, in which the ARVC phenotype was induced by
endurance training (daily swimming) (141), administration
of furosemide and nitrates prevented right ventricular dila-
tion and, in Langendorff preparations, prevented conduc-
tion slowing and reduced the incidence of inducible ven-
tricular arrhythmias. In an accompanying editorial, Calkins
(142) opines that these data may have implications for
treating patients with ARVC. Separately, van der Werf et
al. (143) studied whether flecainide may prevent clinical
arrhythmias in catecholaminergic polymorphic ventricular
tachycardia (CPVT), building on the investigators’ recent
report that flecainide may directly inhibit premature
Ca(2) release and triggered beats in CPVT models in vitro
(144). The investigators collected data from 33 consecutive
genotype-positive CPVT patients treated by flecainide at 8
centers for the endpoint of reduction of ventricular arrhyth- smias during exercise testing. Twenty-two patients had
partial or complete suppression of exercise-induced ventric-
ular arrhythmias with flecainide (p  0.001), and none
ad worsening ventricular arrhythmias. Over a median
ollow-up of 20 months, 1 patient experienced appropriate
CD shocks for polymorphic ventricular arrhythmias. The
nvestigators concluded that flecainide reduced exercise-
nduced ventricular arrhythmias in patients with CPVT that
s not controlled by conventional drug therapy.
The search for risk stratifiers for SCA continues, and this
ear the Journal published the consensus guideline docu-
ent regarding the use of T-wave alternans from the
nternational Society for Holter and Noninvasive Electro-
ardiology (145).
blation of Ventricular Arrhythmias
he ablation of ventricular arrhythmias is largely dependent
n the completeness and quality of either endocardial or
ncreasingly epicardial (146) mapping. It has been demon-
trated that high-quality surface ECG imaging, using math-
matical algorithms to infer the sources of signals on the
eart, can identify important components of the circuit for
entricular arrhythmias noninvasively (147,148). Cuculich
t al. (149) used this approach to noninvasively identify
egions of ventricular scar that were critical for the initiation
nd maintenance of ventricular tachycardia and targeted for
blation. These data continue dramatic recent advances in
maging complex arrhythmias that are significantly improv-
ng the efficacy of ablation for these disorders.
evice Therapy
everal studies have questioned the need for more complex
evices when more simple devices may suffice. Dewland et
l. (150) used data from 104,049 patients in the NCDR
National Cardiovascular Data Registry) to report that the
eriprocedural adverse event rate (3.17% vs. 2.11%; p 
.001) and in-hospital mortality rates (0.4% vs. 0.23%; p 
.001) were higher in 64,489 patients receiving dual-
hamber devices than in those receiving single-chamber
evices. These differences were maintained after multivari-
te adjustment for comorbid conditions. The editorial
ommentary by Al-Ahmad and Freeman (151) places these
ata into perspective, discussing the differences in comor-
idities between populations that may not be fully adjusted
y multivariate analyses and reminding us of the proven
enefits of dual-chamber devices in selected populations.
There is also an increasing focus on the potential hazards
f cardiac implanted device therapy. Morrison et al. (152)
ompared outcomes in 1,030 patients with Medtronic
print Fidelis ICD leads (Memphis, Tennessee) identified
s having a higher-than-expected failure rate compared with
utcomes in 1,641 patients with Medtronic Quattro ICD
eads without this issue, in 3 tertiary care centers. Managed
onservatively, patients with Sprint Fidelis leads had a
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with lead fracture. In the accompanying editorial, Faddis
(153) discusses these data, in the context of the needs for
rigorous monitoring as part of conservative management,
weighed against the potential drawbacks of the aggressive
alternative of replacing Fidelis leads. In a complimentary
study, Swerdlow et al. (154) used novel ICD diagnostics to
discriminate ICD lead fractures (in which electrical imped-
ance rises) from normally functioning leads with a high
impedance or connection problems between the lead and
header. The investigators used a development set of 91 leads
to construct a stepwise algorithm based on ICD diagnostics,
and then they applied this algorithm to an independent test
sample of 100 leads. The algorithm included changes in
impedance, changes in the interval from surgery to imped-
ance rise, and other changes. In the test set, the algorithm
correctly classified 100% of fractures and 87% of connection
problems that had been misdiagnosed as fractures. The
investigators concluded that these methods might have
clinical applicability in separating lead fractures from nor-
mally functioning leads with high but stable impedance.
The problem of inappropriate defibrillator shocks repre-
sents a major source of patient discomfort that can some-
times be psychologically disabling. Van Rees et al. (155)
carefully classified the incidence and predictors of inappro-
priate shocks in more than 1,500 patients. Surprisingly, they
found that inappropriate shocks are both a source of
morbidity, and can predict an increase in mortality, inde-
pendent of whether the patient also received appropriate
shocks.
The ability of resynchronization therapy to reduce the
risk of atrial tachyarrhythmias was studied in MADIT-
CRT. Brenyo et al. (156) classified patients as having small
(20%) or high (20%) decreases in LA volume in
response to CRT. As compared to high responders, the
probability of atrial tachyarrhythmias was increased in
low-responder and ICD-only patients (3%, 9%, and 7%,
respectively; p  0.03). Patients who developed atrial
achyarrhythmias manifested a greater risk for both HF and
eath. Thus, this study demonstrated that CRT could
educe LA volume and result in a subsequent decrease in
trial tachyarrhythmias enhancing the ultimate outcome.
The controversial topic of mandatory electrocardio-
raphic screening of athletes to reduce the risk of sudden
eath was studied by Steinvil et al. (157). During a 14-year
eriod of mandatory electrocardiographic screening, they
ocumented 24 sudden deaths or cardiac arrests in compet-
tive athletes by screening 2 main newspapers in Israel. The
ate of events during these years was not different from the
ncidence during adjacent decades in which mandatory
lectrocardiographic screening was not required. The inves-
igators concluded that the electrocardiographic screening
id not have a significant effect on sudden death in athletes.
n an accompanying editorial, Bove (158) reviews the data
or and against mandatory electrocardiographic, and even
chocardiographic, screening. He points out that the issue isconfounded by the very low incidence of sudden death in
athletes and the frequent prevalence of electrocardiographic
and echocardiographic false-positive abnormalities. Given
the emotional response to the death of an athlete, it is likely
that this controversy will continue.
Advances in CT Imaging
Several studies addressed the expanding role of computed
tomography (CT) imaging in coronary artery disease. Two
studies provided further information on the prognostic value
of coronary calcium scanning. In 5,660 patients in the
MESA (Multi-Ethnic Study of Atherosclerosis), calcium
scores were related to Framingham risk scores (159). The
prevalence of a significant calcium score was low in patients
with very low-risk Framingham score (5%), but became
significantly higher in patients with low-intermediate risk
Framingham scores (5% to 20%). Thus, calcium scoring
in very low-risk Framingham score patients may not yield
reclassification value. Another study analyzed Framingham
risk variables high-sensitivity C-reactive protein and coro-
nary calcium score in 3,966 individuals without known
CAD or acute inflammation (160) to predict hard events
(death, infarction) at 5-year follow-up. Improvement in risk
prediction was provided primarily by coronary calcium
score, but high-sensitivity C-reactive protein was of signif-
icant value in the patients with very low calcium scores. An
accompanying editorial acknowledged the potential use of
calcium score and high-sensitivity C-reactive protein, but
also stated that future studies need to address how these
data can be used to guide therapy in these individuals (161).
Rozanski et al. (162) reported the results of the EISNER
(Early Identification of Subclinical Atherosclerosis by Non-
invasive Imaging Research) prospective randomized trial
examining the impact of coronary artery calcium scanning
on coronary risk factors and downstream testing. They
randomized 2,137 volunteers to either coronary calcium
scanning or no scanning, but not before risk factor coun-
seling. The endpoint was a 4-year change in coronary risk
factors. They observed a mean rise in Framingham risk
score in the no scan group, whereas risk remained un-
changed in those undergoing scanning. In those patients
scanned, increasing calcium score was associated with a
dose-response improvement in multiple risk factors and the
Framingham risk score (p  0.003), whereas costs were
similar in both groups. Thus, coronary calcium scanning
resulted in improved CAD risk factor control without
increasing downstream testing or expenses.
Several studies reported the utility of computed tomog-
raphy angiography (CTA). Using low-dose CT with pro-
spective ECG gating, the mean effective radiation dose was
1.8  0.6 mSv in 612 patients undergoing 64-slice CTA,
with good diagnostic image quality in 96.2% of segments
(163). Meta-analysis of 11 studies with 7,335 patients
undergoing CTA (electron beam in 2 studies, 16-slice in 2
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January 31, 2012:503–37 Highlights From JACC 2011and severity of coronary lesions were predictive of future CV
events, independent of coronary calcification and risk factors
(164). Nonobstructive plaques are also relevant for outcome;
in 2,583 patients from 2 centers, the presence and extent of
nonobstructive lesions better predicted mortality over 3.1
years than the Framingham risk score did (165). An
accompanying editorial (166) stressed that it would be very
important to better define plaque composition to further
improve risk stratification. In another important paper on
the value of CV CTA, Kristensen et al. (167) demonstrated
the prognostic implications of having nonobstructive CAD
in patients with non-STEMI. They followed 312 patients
for a median period of 16 months, documenting the
relationship of nonobstructive lesions with cardiac events
(HR: 1.18 per 100-mm3 plaque volume increase; p  0.01).
Neither Agatston score nor the amount of calcium in
atherosclerotic plaques was associated with an increased risk
of cardiac events. The latter findings further support previ-
ous and recent studies published in the Journal and other
ournals documenting the absence of absolute protection in
ymptomatic patients with 0 calcium score.
The prognostic value of CTA was derived from an
nternational multicenter registry of 24,775 patients under-
oing 64-slice CT, with follow-up of 2.3 years (168).
bsence of coronary disease on CTA was associated with
xcellent outcome (annualized death rate: 0.28%); the mor-
ality increased in parallel with severity and extent of
tenoses. In an accompanying editorial, De Bruyne and Van
ieghem (169) emphasize that, in addition to assessing
uminal obstruction, it will be important to evaluate the
emodynamic significance of these stenoses for proper
atient management. The power of cardiac CT to define
rognosis was reported in a meta-analysis by Hulten et al.
170). In that comprehensive study, the investigators com-
iled data from 18 reports that evaluated 9,592 patients with
median follow-up of 20 months. Very importantly, the
ooled negative likelihood ratio for MACE after a normal
T angiographic exam was 0.008 (95% CI: 0.0004 to 0.17;
 0.001), whereas the pooled annualized event rate for
atients with at least 1 50% coronary stenosis versus
ormal CTA was 8.8% versus 0.17% per year for MACE
p  0.05) and 3.2% versus 0.15% for dearth or nonfatal
nfarction (p  0.05). The investigators concluded that
dverse CV events in patients with normal CTA are rare
nd that incremental rates of MACE are associated with
ncreasing CAD by CTA. Finally, Chow et al. (171)
emonstrate the potential use of coronary opacification in
T angiography to estimate the presence of coronary flow
bstruction. In this proof-of-concept study involving 52
atients, normal coronaries were compared for coronary
pacification with vessels containing 50% obstructions or
ith abnormal TIMI flow grade (3). The investigators
ound that coronary opacifications across stenoses were
elated to abnormal TIMI flow grade. The findings from
his innovative pilot investigation were discussed in an
ccompanying editorial by Rybicki (172), who was among ahe first to propose the concept of coronary opacification
nalysis for the detection of CAD.
FFR can assess the hemodynamic significance of a ste-
osis, but has thus far required invasive angiography.
ecently, the feasibility of assessing FFR noninvasively has
een reported (173). In a multicenter study including 103
atients (and 159 vessels), FFR derived from CTA was
ompared to invasively assessed flow reserve. The agreement
etween the 2 approaches was good (r  0.717; p  0.001),
ith minimal underestimation by CTA. The accuracy of
TA to detect hemodynamically significant obstruction
ompared with invasive FFR improved from 58.5% when
he stenosis severity was used to 84.3% when the CTA-
erived FFR was used. Further studies are needed, but this
TA approach may allow integrated assessment of anatomy
nd functional consequences (174).
A 16-center study evaluated the use of CTA for acute
hest pain evaluation in the emergency room; 361 patients
ere randomized to CTA and 338 to myocardial perfusion
maging (175). The CTA approach reduced time to diag-
osis (primary endpoint) by 54% compared with myocardial
erfusion imaging and reduced cost by 38% compared with
tandard care. The rate of major adverse events at 6 months
as similar (0.8% and 0.4%, respectively) in patients in
hom CTA and perfusion imaging was normal. In an
ccompanying editorial, Salerno et al. (176) emphasized
hat some patients may benefit more from functional imag-
ng for ischemia and others by direct visualization of the
oronary arteries; the choice should be individualized.
dvances in Cardiac Imaging
ith the increasing use of rubidium Rb 82 positron
mission tomography (PET), it becomes feasible to both
ssess perfusion defects and evaluate regional myocardial
ow reserve (MFR) in a quantitative manner. In 51 patients
ith atherosclerosis on CTA, rubidium Rb 82 PET-
easured MFR varied significantly among individual coro-
ary stenoses (177). Importantly 38% of nonobstructive
tenoses also had abnormal flow reserve. On a patient basis,
redictors of reduced MFR were the modified Duke coro-
ary artery disease index and the number of segments with
ixed plaque. Importantly, CTA variables had only modest
alue in predicting MFR, and further studies are needed to
etermine the relation between coronary plaque character-
stics and MFR (178).
The prognostic value of impaired MFR was evaluated in
04 patients undergoing rubidium Rb 82 PET with a
edian follow-up of 387 days. Quantitative MFR provided
ncremental prognostic value over visual assessment of
erfusion defects (summed stress score) (179). These find-
ngs stress the potential advantage of quantitative perfusion
ssessment over visual interpretation (180). Another quan-
itative PET perfusion study employed 13N ammonia and
emonstrated that a reduced coronary flow reserve (defined
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sion was visually evaluated (by summed stress score), a
relation was found for only 1 plasma biomarker, supporting
the superiority of absolute quantification of coronary flow.
Fluorodeoxyglucose F-18 (FDG) with PET permits as-
sessment of regional inflammation. In patients with in-
creased periodontal uptake, there was also an increased
FDG uptake in carotid arteries and the aorta, suggesting
vascular inflammation, which was confirmed histologically
in patients undergoing carotid endarterectomy (182). These
findings suggest a global process of inflammation, rather
than a regional phenomenon. Another study used FDG
PET imaging to evaluate valvular inflammation in patients
with AS (183). Interestingly, patients with mild and mod-
erate AS had increased FDG uptake, whereas patients with
heavily calcified, severely stenotic aortic valves did not.
These observations suggest active valvular inflammation
occurs early in the development of AS and is reduced in
end-stage disease.
This year, the cutting edge development in CV imaging
clinical investigation was set by magnetic resonance meth-
ods to assess myocardial fibrosis, Dweck et al. (184) re-
ported that mid-wall pattern of myocardial fibrosis defined
by MRI delayed enhancement (n  54) was the strongest
ndependent predictor of all-cause mortality by multivariate
nalysis (HR: 5.35; p  0.03) among 143 nonischemic
ardiomyopathy patients followed for 2.0 years. An editorial
y Nazarian (185) opines that these results raise important
uestions about mechanisms of mid-wall fibrosis in patients
ith LV overload and nonischemic cardiomyopathy, as well
s its potential relationship with sudden death and ultimate
echanical failure. Myocardial fibrosis was also related to
he risk of sudden death in patients with severe LV
ysfunction. Iles et al. (186) followed 103 patients for
rimary prevention of sudden death for 573 days and
emonstrated a 29% discharge rate among nonischemic
ardiomyopathy patients with fibrosis by MRI versus 14%
ith ischemic cardiomyopathy. By contrast, there were no
ischarges with nonischemic cardiomyopathy without de-
ayed enhancement. In a different study, Daccarett et al.
187) related the presence of LA fibrosis to a history of
troke in 387 patients with AF referred for ablation.
atients with previous strokes had a greater percentage of
A fibrosis (24.4% vs. 16.2%; p  0.01) than those without
istory of stroke. Barbier et al. (188) published an extension
f these observations to populations by documenting in a
ommunity-based study that the presence of MI by clinical,
CG, and MRI criteria was related to presence of cerebral
nfarction defined by contrast-enhanced MRI.
The cardiac-cerebral connection received increasing at-
ention this year. Rodriguez et al. (189) documented the
elationship between mitral and aortic annular calcification
nd aortic sclerosis by echo and cerebral infarction by MRI
mong 2,680 participants of the Cardiovascular Health
tudy without clinical history of stroke or transient ischemic
ttacks. The degree of annular or valvular calcification was fiirectly related to the presence of covert cerebral alterations
y MRI. In another study, Lee et al. (190) performed
agnetic resonance angiography to assess the presence and
everity of intracranial and extracranial atherosclerosis in
,367 patients before CABG. Strokes within 14 days from
peration (n  33) were independently associated with the
therosclerotic score (OR: 1.35). The study suggests that
he pre-operative evaluation of cerebral arteries by MR
ngiography may be useful to predict the likelihood of
ost-CABG stroke. Noguchi et al. (191) documented the
elationship between coronary events and high-intensity
ignals observed in carotid plaques by inversion recovery
-dimensional T1-weighted imaging. Noguchi et al. (191)
demonstrated a potential link between carotid and coronary
plaque vulnerability because high-intensity inversion recov-
ery 3-dimensional T1-weighted imaging signals were the
strongest independent predictor of cardiac events among
217 stable CAD patients followed up to 72 months (HR:
3.15; p  0.0001) compared with carotid intima-media
thickness and coronary risk factors in multivariate analysis.
State-of-the-art MRI techniques to further the noninva-
sive evaluation of myocardial perfusion evolved in 2011.
Lockie et al. (192) employed 3.0-T MRI perfusion imaging
to study the relationship between myocardial perfusion
reserve estimated by Fermi deconvolution and invasive
fractional flow reserve. Using receiver-operator characteris-
tic analysis, the investigators found that the method had an
area under the curve of 0.89 to identify lesions that had FFR
0.75. In a related study, Manka et al. (193) used
3-dimensional dynamic stress MRI at 3-T to quantify the
“volume” of perfusion defects before and after coronary
intervention in 48 patients. Percentage of LV volume
subtended by the hypoenhanced defect during adenosine
stress was reduced from 14.2 to 3.2 by coronary stenting.
Additionally, state-of-the-art strain imaging by strain-
encoded MRI was used to detect regional myocardial
dysfunction during dobutamine stress before the onset of
visually obvious wall motion abnormalities. In 320 patients
with suspected CAD followed for 28 months, 67 events
occurred. Stress-induced wall motion abnormalities in-
creased the ability to predict cardiac outcomes relative to
clinical variables (chi-square: 39.3 vs. 13.0). Adding quan-
titative strain analysis by strain-encoded MRI further in-
creased predictive power (chi square: 52.5; p  0.01).
inally, McGann et al. (194) documented the power of
icrovascular obstruction defined by contrast-enhanced
RI to predict atrial scar formation in patients undergoing
blation for AF. In 37 patients imaged immediately after
blation, equal numbers of atrial wall segments were classi-
ed as hypo-enhanced (34 due to profound microvascular
njury and obstruction), hyperenhanced (38  13% due to
yocyte injury without profound microvascular damage),
nd normally enhanced (28  11% minus preserved myo-
yte wall integrity and microvasculature). However, 3
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January 31, 2012:503–37 Highlights From JACC 2011mediately after ablation as opposed to 31% to hyperen-
hanced segments and 10  5% to normally enhanced
egions. Because scar formation correlates with procedure
utcomes, the study highlighted the use of magnetic reso-
ance techniques to aid in the prediction of success from AF
blation procedures.
Echocardiography studies also make the list of the best in
he Journal this year. In a study using established strain
maging by echocardiography, Fallah-Rad et al. (195) dem-
nstrate that lateral S= by tissue Doppler as well as peak
lobal longitudinal and radial strain measures signaled the
resence of myocardial dysfunction before ejection fraction
ecame abnormal in patients being treated for breast cancer
ith trastuzumab. Ten of 42 patients under therapy devel-
ped tissue Doppler and strain abnormalities 3 months
efore reduced ejection fraction could be detected. The
mportance and implications of these findings are discussed
y accompanying editorial by Edvardsen (196) emphasizing
he ability of strain measurements to detect myocardial
bnormalities prior to conventional wall motion and ejec-
ion fraction.
In another study, established MRI LV mass quantifica-
ion was employed to quantify the impact of impaired
ulmonary flow on LV underloading and atrophy. Hardzi-
enka et al. (197) studied LV mass measured by MRI in 36
atients with chronic thromboembolic pulmonary hyperten-
ion and showed that these patients had lower LV mass
han normal volunteers did. Moreover, LV mass increased
fter pulmonary endarterectomy (from 38 to 44 g/m2) as
ight ventricular ejection fraction improved from 31% to
6% (p  0.001 for both). The implications of these
ndings to the field of pulmonary hypertension are placed in
erspective by accompanying editorial by Dell’Italia (198).
Patients with large hiatal hernias often complain of CV in
ddition to gastrointestinal symptoms. Naoum et al. (199)
eported exertional dyspnea was present in 25 of 30 hiatus
ernia patients despite normal baseline respiratory function.
ignificant LA compression was present in 23 of 30 patients
n CT, whereas pulmonary vein and coronary sinus com-
ression was present in 11 and 26 of the 30 patients. After
urgical treatment, resolution of cardiac compression was
ocumented and exercise capacity improved significantly. In
act, LA diameter change by echo was the only independent
redictor of exercise capacity improvement after hiatal
ernia surgery. An accompanying editorial by Marwick
200) points out that this is a common clinical issue.
iomarkers
atriuretic peptides. In a significant report, The PROTECT
rial by Januzzi et al. (201) was a prospective single-center
tudy that drove N-terminal pro–B-type natriuretic peptide
NT-proBNP) levels1,000 pg/ml in patients with systolic
ysfunction (201). With a mean follow-up of 10 months,
here was both a significant decrease in NT-proBNP levels
nd events and an impact on quality of life. In an accom- tanying editorial, Maisel (202) pointed out that the defini-
ion of an ideal biomarker should include those that are
linically actionable, can be used for “biomarker-guided
herapy,” and could also be “biomonitored” during treat-
ent as an effective surrogate of improvement.
DeFelippi et al. (203) found that the addition of an
bnormal LVEF to a low baseline NT-proBNP level did
ot improve estimation risk for HF in older adults. An
nitially elevated or rising NT-proBNP level was associated
ith an increased risk of developing an abnormal LVEF. In
n accompanying editorial, Richards (204) opined that,
iven the accumulating evidence, we should consider con-
rolled therapeutic trials in patients with combinations of
re-defined NP and echocardiographic abnormalities.
Lam et al. (205) studied the relationship between sex
ormones and natriuretic peptide levels in community-
ased adults. They found that the higher circulating NT-
roBNP concentration in women was related to the lower
evels of circulating androgens and the potentiating effect of
xogenous female hormone therapy. In an accompanying
ditorial, Clerico (206) points out that although the effects
f androgens (inhibitory) and estrogens (excitatory) clearly
nfluence cardiac endocrine function, we still lack informa-
ion on how this balance exerts its influence in either sex
hroughout the human lifespan.
Even though natriuretic peptides are independent predic-
ors of CV events in noncardiac and vascular surgery,
odseth et al. (207) performed a meta-analysis to examine
hether their addition to clinical risk indexes might im-
rove pre-operative risk stratification. Their findings were
ositive, especially in the intermediate-risk group with a net
eclassification improvement of 84%. This adds to the
rowing data promoting the use of natriuretic peptides on
op of clinical criteria for pre-operative evaluation.
CS. To assess whether very small increases in troponin T
easured by high-sensitivity assay could reflect ischemia
ithout necrosis, Turer et al. (208) took serial coronary
inus samples from 19 patients during rapid atrial pacing.
rief periods of ischemia, without frank infarction, caused
ow-level troponin T increases, even in those with no
emonstrable coronary disease. In an editorial, White (209)
uggested that there are 5 potential pathobiological mech-
nisms other than coronary necrosis for troponin release:
poptosis; normal myocyte cell turnover; cellular release of
roteolytic troponin degradation products; increased cellular
all permeability; and formation and release of membra-
ous blebs.
Body et al. (210) evaluated chest pain patients with both
standard and a high-sensitivity troponin T assay (see also
aisel [202]) and found that all MI patients had detectable
igh-sensitivity troponin T measurements on the first blood
raw. A 99% negative predictive value was seen in an
dditional clinical practice cohort. In an accompanying
ditorial, Peacock (211) points out that a specific test is of
reat value because it indicates who will need an interven-
ion, and a poorly sensitive test is of little value to an
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be sent home based on a negative result. He points out that
further troponin testing if the first is negative is of little
value with the assay in this study. Thus, as we characterize
high-sensitivity assays, we may be able to more accurately
rule out patients at the time of presentation.
Damman et al. (212) investigated whether multiple
biomarkers improved prognostication in 1,034 STEMI
patients undergoing primary intervention. In a Cox regres-
sion analysis, glucose, glomerular filtration rate, and NT-
proBNP best predicted mortality and were the basis of a
score that identified a high-risk STEMI group undergoing
acute intervention. In an accompanying editorial, Biasucci
et al. (213) noted that this study provides important
pathophysiological information confirming the common
roots of ACS (STEMI vs. non-STEMI vs. unstable angina)
and promising clinical improvements in STEMI treatment.
Cardiac troponin has become the biomarker of choice for
myocardial injury due to its specificity to myocardium.
However, Jaffe et al. (214) detected elevated troponin T but
normal troponin I in 16 patients with skeletal myopathies.
All antibodies used for troponin T assay were immunore-
active with a protein obtained from 4 skeletal muscle
biopsies. Thus, certain skeletal muscle diseases can cause an
increase in circulating levels of troponin T and lead to the
false-positive diagnosis of cardiac injury.
Arrhythmias. Plasma von Willebrand factor has been re-
lated to stroke and vascular events in AF. Roldan et al. (215)
demonstrated that von Willebrand factor levels were an
independent risk factor for bleeding and stroke in 829
anticoagulated AF patients, who were followed for 2 years.
In an accompanying editorial, Serebruany (216) points out
that we should measure von Willebrand factor serially in AF
patients to better validate this promising biomarker, espe-
cially in groups that are using direct thrombin inhibitors.
Renal. Early markers of renal injury are on the front burner
of biomarker research. Hasse et al. (217) performed a
multicenter-pooled analysis of prospective studies on the
role of neutrophil gelatinase-associated lipocalin in subclin-
ical kidney injury. Examining pooled data from 2,322
critically ill patients, they detected likely subclinical kidney
injury in the absence of diagnostic increases in serum
creatinine. These patients also had increased risk of adverse
outcomes. In an accompanying editorial, McCullough et al.
(218) suggest that neutrophil gelatinase-associated lipoca-
lin, and perhaps other early injury biomarkers alone or in a
multimarker panel, might be valuable in patients in whom
creatinine has not yet changed. This could lead to new
therapies, allowing us to better prevent further renal
damage.
Renal injury is a serious problem in patients admitted
with acute HF. Manzano-Fernandez et al. (219) prospec-
tively studied 200 hospitalized patients with acute HF and
reported that, whereas neither beta trace protein nor cystatin C
was associated with worsening renal function, during hos-
pitalization, both were superior to standard measures ofrenal function for prediction of death and rehospitalization.
Chen (220), in an editorial, recommends further studies to
assess the prognostic value of beta trace protein in various
CV diseases such as CAD, hypertension, and diabetes.
Treatment. In an effort to demonstrate efficacy of natri-
uretic peptide infusion, 303 patients with CKD undergoing
CABG were randomized to carperitide or placebo (221). In
the post-operative acute stage, Carperitide showed cardiore-
nal protective effects that prevented post-operative cardiac
events and initiation of dialysis. In an accompanying edito-
rial, Boerrigter and Burnett (222) pointed out that although
many questions remain as to the usefulness of guanylyl
cyclase agonists as therapeutic agents, it remains a thera-
peutic target worthy of further study.
Vigorous physical activity is known to reduce the risk of
CV disease. Although it might seem intuitive that being
sedentary should increase the risk of CV disease, this
question has not been carefully examined. Stamatakis et al.
(223) examined whether “screen time”—the number of
hours in front of the television or computer—was associated
with future CV events in 4,512 individuals. They found a
dose-response relationship between screen time and the risk
of CV events, even after adjusting for known risk factors and
time spent in moderate and vigorous physical activity.
Individuals with 2 h of screen time a day had a 2.2-fold
increase in CV events.
Outcomes
The American Heart Association recently identified 7
characteristics of “ideal” CV health: not smoking; BMI25
g/m2; regular physical activity, either moderate (150 min/
week) or vigorous (75 min/week); a healthy diet (4
components); total serum cholesterol 200 without medi-
cation; blood pressure 120/80 mm Hg without medica-
tion; and fasting blood glucose 100 without medication.
Whereas anyone who met all 7 of these criteria would
clearly be classified in ideal CV health, can many Americans
actually make the grade? The ARIC (Atherosclerosis Risk
in Communities) investigators (224) addressed this question
in 12,744 individuals free of CV disease, mean age 54 years.
The results were disheartening: only 17 participants in the
study (0.1%) were in ideal CV health, and only 2.8% met 6
of the 7 criteria. Conversely, 82.5% of the ARIC population
were judged to be in “poor” CV health.
Public reporting of the outcomes of CV procedures has
been mandated in several states. This well-intentioned
practice could, however, have unintended adverse conse-
quences if doctors avoided treating the sickest patients. The
Massachusetts Angioplasty Registry addressed this concern
by adding data elements to its reporting form that captured
objective information on critically ill patients about to
undergo PCI: coma on presentation; active hemodynamic
support; and ongoing cardiopulmonary resuscitation (225).
Patients who met 1 or more of these compassionate use
criteria were 27 times as likely to die in the hospital and
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accuracy of the hospital outcomes reports.
The use of invasive coronary angiography varies consid-
erably across the United States. Douglas et al. (226) used the
NCDR to examine the results of elective coronary angiog-
raphy at the hospital level, omitting patients with known
coronary disease (prior ACS, MI, PCI, or CABG). There
were 691 hospitals with at least 50 such cases per year, with
an average rate of obstructive disease of 45%. There was far
more variation in the rate of positive angiograms than
expected by random chance: 91 hospitals (13%) had fewer
than 35% patients with obstructive CAD, whereas 82
hospitals (12%) had at least 75% with obstructive CAD.
Much of this variation was explained by patient character-
istics, with the pre-test likelihood of CAD of 0.39 in the
lowest quartile of hospitals, compared with 0.55 in the
highest. Although it is unclear whether there is an optimal
rate of CAD at the time of angiography, the substantial
interhospital variation in this rate should be examined
further.
A fascinating communication regarding national spend-
ing on CV disease was received by the Journal. Miller et al.
(227) developed time series estimates of the portion of the
National Health Expenditure Accounts devoted to CV ICD
codes in the International Classification of Diseases-Tenth
Edition. They found that overall spending on CV disease
grew at a compound annual growth rate of 5.7% since 1996,
which is somewhat less than the overall rate of growth of all
expenditures during the same period. Spending on preven-
tion was higher for CV disease than for other categories and
grew to more than 20% of total CV expenditures. Con-
versely, spending on CV research amounted to roughly 1%
of CV expenditures in recent years. Obviously, these data
cannot indicate whether the money has been well spent.
However, the data do indicate that expenditures for CV
disease have not increased inordinately over this 12-year
span, have increasingly been devoted to prevention, and
have supported research to only a small extent.
A study by Kim et al. (228) reported the degree of
international participation in CV randomized control trials
sponsored by the National Heart, Lung, and Blood Insti-
tute. Of 24 studies examined, 19 included international
participation with a median of 9.5% of patients contributed
from outside the United States. CAD trials had nearly 50%
international enrollment. Many of the trials that had great-
est influence on clinical practice had a majority enrollment
from outside the United States. Given the many genetic,
environmental, and cultural differences between popula-
tions, these findings raise questions regarding the applica-
bility of trial data to patients in the United States, and the
ability of institutions within the country to enter patients
into trials. In an accompanying editorial, Califf and Har-
rington (229) discuss the “offshoring” of clinical research
from the United States and question whether the American
clinical research enterprise can be competitive. While rec-
ognizing that globalization of clinical research is a powerfulsocial good, they recognize that the results obtained may not
reflect those that will be achieved in a different population.
They provide 5 recommendations to transform the clinical
research system in the United States.
With the increasing emphasis on quality of clinical care,
Yang et al. (230) examined the correlation of hospital
performance for acute MI with that of HF from the
GWTG program. They compared core measures for these 2
disorders in 283 hospitals. Only a modest correlation
between hospital performance for these 2 entities was
observed (r  0.50). However, hospitals that had consis-
tently superior performance for both infarction and HF care
had significantly lower risk-adjusted mortality than those
with superior performance for either alone. Thus, excellent
hospital quality for 1 cardiac disorder does not necessarily
apply to others; however, high-quality performance for
multiple disorders translates into superior outcomes.
A challenge for clinicians is to prescribe an effective
warfarin dose that avoids both hemorrhage and thrombosis
(231). Does genetic testing improve dosing? The 2 genes
shown to have the greatest impact on predicting warfarin
dose are CYP2C9 and VKORC1. The study from Finkelman
et al. (232) from 1,378 patients at 3 anticoagulation centers
showed that clinical data and genetic information combined
in an algorithm provided the best predictor for warfarin
dose. These findings combined with the MM-WSE
(Medco-Mayo Warfarin Effectiveness Study), comparing
6-month incidence of hospitalization of patients receiving
warfarin genotyping versus an historical control group,
would argue in favor of clinical effectiveness of genetic
screening for individuals on warfarin (231).
Genetics/Genomics
Our textbook understanding of atrial natriuretic peptide as
a neurohormone is rapidly evolving. Cannone et al. (233)
provide new data showing an association between individ-
uals harboring the minor allele of single nucleotide poly-
morphism (SNP) rs5068 in atrial natriuretic peptide and a
favorable cardiometabolic profile. Approximately 10% of the
population harbored 1 copy of the minor allele, which was
associated with lower blood pressure and BMI and higher
levels of pro-atrial natriuretic peptide. The genotype fre-
quencies for this SNP were similar to those reported in
previous studies (Framingham Heart Study, Malmo Diet,
and Finrisk97) (234).
The hunt is still on for SNPs in the chromosomal region
9p21.3 that increase risk of CAD. Ardissino et al. (235)
showed that individuals harboring the SNP rs1333040 in
the gene desert on chromosome 9p21.3 have an increased
likelihood of undergoing a subsequent revascularization
procedure following MI. An association was also found
between this SNP and the progression of atherosclerosis as
measured by the Duke Coronary Artery Disease Index. No
association was found between this SNP and death or
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Highlights From JACC 2011 January 31, 2012:503–37Anderson (236) provided a framework highlighting the
strengths of this study in better understanding the
phenotype. Harismendy et al. (237) identified 33 enhanc-
ers in the 9p21 gene desert, demonstrating that this
interval is the second densest rich region with enhancers
in the entire genome and providing a potential mecha-
nism for how the SNPs may be associated with progres-
sion of atherosclerosis and risk of revascularization.
The controversy over whether individuals with the KIF6
Trp719Arg genotype showed greater response to statin
therapy may have ended. A study by Hopewell et al. (238)
in 18,348 individuals showed that the effect of simvastatin
therapy was similar (i.e., reduced the incidence of coronary
and other major vascular events) irrespective of the KIF6
Trp719Arg genotype. Thus, this large study supports an
effective role for statins in decreasing CV events regardless
of one’s KIF6 genotype. Similarly, Kapplinger et al. (239)
showed the background noise in genetic testing results
focusing on mutations in the genes associated with ARVC.
These investigators screened 93 probands with ARVC/
dysplasia and 427 presumably healthy control subjects for
deoxyribonucleic acid variants in the coding exons/splice
junctions of PKP2, DSP, DSG2, DSC2, and TMEM43.
ompared with 58% of individuals with ARVC, the back-
round noise, or percent of “healthy” control subjects that
anifested mutations in these genes was 16%, a high value
ompared to the percentage of “healthy” control subjects
ith mutations in long-QT genes (240). These findings
tress the importance of genetic counseling and careful
nterpretation of the genetic tests. Kapplinger et al. (239)
id provide the pathogenic likelihood of different deoxyri-
onucleic acid variants from a positive ARVC genetic test
esult, grouping mutations that included insertions/
eletions, splice junctions, and nonsense mutations as “rad-
cal mutations” and the most likely pathogenic. Missense
utations were binned as variants of undetermined signif-
cance and then subdivided into more or less likely to
nfluence pathogenicity. When split into these subgroups,
adical mutations were only found in 0.5% of control
ndividuals versus 43% of ARVC cases, whereas missense
utations were found in 16% of control subjects and 21% of
RVC cases. This study was accompanied by an editorial
rom Mestroni and Taylor (241) that focuses on the
mportance of expertise to help separate pathogenic muta-
ions from background noise, as well as family history to aid
n the interpretation.
Mounting evidence suggests that disruptions/mutations
n ion channels lead to dilated cardiomyopathy (DCM) and
rrhythmias. McNair et al. (242) showed that both previ-
usly established and novel mutations in the ion channel
ene, SCN5A, are associated with DCM. How mutations in
odium channels are associated with DCM is not entirely
lear. Towbin and Lorts (243) speculate that mutations in
CN5A leading to DCM may be caused by disruption of
ytoskeletal binding partners to SCN5A, electrical dysfunc-
ion caused by the channel leading to mechanical instability, myocardial dysfunction and ventricular dilation, or primary
isruption of a channel leads to DCM. Two-thirds of the
utations were localized in the highly conserved S3 and S4
ransmembrane segments, which has previously been shown
o regulate voltage-sensing of the channel (242). This
urrent study from McNair et al. is important in that it
aises new questions including: Do variants in SCN5A lead
o DCM in the absence of arrhythmias?
Barc et al. (244) provided the first evidence of copy
umber variants (deletions) in the genes KCNQ1 and
CNH2 in 3 unrelated families segregating with the LQTS
henotype. Over 90% of the genotyped cases of LQTS are
ue to mutations in KCNQ1, KCNH2, and SCN5A. How-
ver, these mutations are base change mutations, not copy
umber variants in which stretches of deoxyribonucleic acid
re either inserted or deleted. Barc et al. (244) identified
eletions in KCNQ1 and KCNH2. The deletion in KCNH2
ncluded the entire gene, likely leading to haploinsufficiency.
his deletion in KCNH2 perfectly cosegregated between the
henotype and the copy number variant inheritance in the
amily, strongly suggesting this deletion was responsible for
he effect. The other 2 deletions in KCNQ1 were not fully
enetrant, leaving unanswered questions. This study opens
p new directions for the field of LQTS (245).
The mechanisms explaining why diabetic patients present
ith high platelet PR are not clear. A study by Angiolillo et
l. (246) provides evidence that diabetic patients that carry
he C allele of the rs956115 marker of the IRS-1 gene
approximately 20% of patients) have a hyper-reactive plate-
et phenotype and increased risk of major adverse CV
vents. This association did not hold true for patients
ithout diabetes and the mechanism is unknown. The
linical implications of this study are that diabetic patients
ay benefit from antithrombotic treatments that are per-
onalized to their disease status and genotype. The
s956115C allele was also an independent predictor of major
dverse CV events—independent of the hyper-reactive
latelet phenotype— suggesting that mutations in the
RS-1 gene may be important predictors for diabetic pa-
ients of CV disease.
The Journal published a state-of-the-art paper from
’Sullivan et al. (247) that reviews and explores the poten-
ial role of microribonucleic acid–guided therapy for the
revention of plaque rupture and in-stent restenosis. The
aper focuses mainly on miR-143 and -145. In addition to
n elegant review of clinically relevant biology, these inves-
igators address delivery of microribonucleic acid–based
herapeutics with an eye on the past and the future.
The quest continues for optimizing stem cell repair of the
eart after a myocardial infarction. A pre-clinical study with
combined gene therapy approach (sonic hedgehog gene
ransfer to improve angiogenesis) and AMD3100 adminis-
ration (to induce mobilization of progenitor cells) improved
ardiac functional recovery (248). Combination therapy
ignificantly increased (nearly doubled) the number of bone
arrow–derived progenitor cells in the myocardial endo-
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MI. Whether this is the reason why LVEF improved
significantly in the group of mice receiving the combination
therapy is not clear. Combination therapy also resulted in a
significant reduction in fibrosis. Identification of efficacious
combination therapies for a class of patients that promotes
the mobilization of endogenous progenitor cells to the heart
to improve the coronary circulation and improve myocardial
function will continue to be an area of growing research.
The Best in JACC also provides an Update for 2011 on
the clinical and genetic issues in familial DCM by Hersh-
berger and Siegfried (249). A section in this state-of-the-art
paper that is particularly helpful for clinical care is the flow
diagram in Figure 1 providing guidance in straightforward
steps for determining new idiopathic or familial DCM
diagnoses. Information is provided on genetic counseling, as
well as what has changed and what has not changed in the
past 5 years.
Pediatric Cardiology
A study from the Boston Children’s Hospital describes a
large experience with primary cardiac tumors in children
and characterizes associated rhythm disorders. A single-
center review studied 173 patients from 1968 to 2010 (250):
106 had rhabdomyoma; 25 fibroma; 14 myxoma; 6 other
vascular; 4 teratoma; 3 lipoma; and 15 other tumors. The
age of diagnosis was pre-natal to 21 years with a mean age
of 7 months. Ventricular tachycardia was the single most
common type of arrhythmia that announced a cardiac
tumor. Surgical excision for rhabdomyomas and fibromas
was an effective management in eliminating ventricular
arrhythmias.
Another study from Toronto used MRI to characterize
cardiac tumors from a multicenter experience (251). They
collected 78 cases from 15 centers in 4 countries: 30
fibromas; 14 rhabdomyomas; 12 malignant tumors; 9 hem-
angiomas; 4 myxomas; 3 teratomas; 2 other tumors. Re-
viewers blinded to histologic diagnosis identified the correct
type of tumor in 97 cases, but also included a differential
diagnosis in 42% of the cases. The conclusion was that MRI
could predict the tumor type in the majority of children,
especially with a comprehensive imaging protocol that
included steady-state free precession, T1- and T2-weighted
contrast imaging, and myocardial gadolinium contrast im-
aging as well. An editorial comment by Bardo (252) points
out that, to some extent, there was a selection bias against
rhabdomyomas, which, though the most common form,
might not be referred. She points out that MRI potentially
joins molecular imaging, to include PET and/or some
hybrid MR/PET combination and/or specific molecularly
targeted agents that might be attached to gadolinium or iron
oxide.
Another study examined the issue of recurrent obstruc-
tion and the need for reintervention in patients who have
already undergone balloon aortic dilation for arch obstruc-tion after the Norwood procedure for hypoplastic left heart
(253). The investigators studied 116 patients who under-
went balloon dilation from 1983 to 2009. A significant
proportion of these patients required a reintervention for
residual arch obstruction, especially those who had obstruc-
tion proximal to the left subclavian artery. The investigators
emphasized that there really are diffuse aortic abnormalities
in the reconstructed aortic arch after Norwood procedure,
and that this represents ongoing risk. A helpful editorial
by, Lamberti (254) contrasts this information with a
smaller series that did not come to the same conclusion.
The Bautista-Hernandez group suggested that coarctec-
tomy at the time of Norwood was protective of late
coarctation. The publication in the Journal concludes that
coarctation at the time of Norwood procedure is not
persistent and the problem of late coarctation after the
Norwood procedure has not been solved.
In a paper addressing the optimal antithrombotic regi-
men after the Fontan procedure from Australia and To-
ronto, Canada, 111 patients were randomized: 57 to aspirin
and 54 to heparin/warfarin (255). Transthoracic and trans-
esophageal echoes were performed for surveillance, and
major bleeding and death were the primary adverse out-
comes. In the heparin/warfarin group, there were 13 throm-
boses with 3 determined clinically and 10 by routine echo.
Similarly, 12 thromboses occurred in the aspirin group, 4
were found clinically and 8 by routine echo. Overall freedom
from thrombosis 2 years after Fontan surgery was only 19%.
Thus, alternative antithrombotic approaches will need to be
considered. In an editorial comment, Canter (256) acknowl-
edges the results of the study and points out that it
confirmed another study by Jacobs and Geary in 2002 (257)
and then states that it is likely that newer anticoagulants
undergoing evaluation in adults with AF will need to be
tested in Fontan patients. Canter (256) then references a
paper by Schirmer et al. (258), enabling the beginning of
phase 2 and 3 clinical trials on factor Xa and inhibitors
rivaroxaban, apixaban, betrixaban, and edoxaban.
A multicenter study from Australia, Europe, and the
United States described the first percutaneous tricuspid
valve replacement using the Melody pulmonary valve
(Medtronic) in patients with congenital or acquired tricus-
pid disease in 15 patients (259). The indications for tricus-
pid intervention included severe hemodynamic compromise
and high perceived surgical risk. All had had previous
tricuspid surgery and had significant stenosis and/or regur-
gitation of the bioprosthetic valve for right atrial to right
ventricular conduit. Technical success was achieved in 12
patients; the only procedural complication was third-degree
heart block. One patient developed tricuspid valve endocar-
ditis 2 months after implant and 1 had multiorgan failure
and did not improve. The majority of valves were placed via
femoral or internal-jugular approach. The advent of a newer
Melody valve beyond 22 mm, or other suitable bioprosthetic
implantable valves, will open a new window for therapy. As
Moore (260) points out in his editorial comment, reporting
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outcomes. It does open the door for use of larger-diameter
valves, such as the Sapien valve, to extend the range of
applicable valve annuli or patients who may be eligible for
percutaneous valve therapy.
A large study from Germany, China, and the United
States reviews 92 patients (mean age: 7 years 12 days to 18
years) who received single- or biventricular assist device
support (261). The devices included the Berlin Heart
EXCOR ventricular assist device (VAD), the Berlin Heart
Incor VAD, the World Heart Novacor VAD (Salt Lake
City, Utah), and the HeartWare VAD. Thirty-day and
6-month survival was 82.9 5.3% and 67.8 7.5% for LV
assist devices and 63.5  8.9% and 37.9  10.5% for
biventricular support. The report provides a comprehensive
overview of implantation of VADs in younger patients.
VAD mortality was increased in children who had congen-
ital heart disease and those who had a pre-operative require-
ment for norepinephrine.
A paper from the Mayo Clinic (262) reviews the out-
comes of 46 patients with congenitally corrected transposi-
tion of the great arteries undergoing systemic atrioventric-
ular (AV) valve replacement, 27 of whom had pre-operative
systemic ventricular ejection fraction (SVEF) of  40% and
19 with 40%. All had good-sized ventricles. Pre-operative
SVEF was the only independent predictor of 1-year sur-
vival. SVEF 40 was preserved in 63% of the patients who
underwent surgery with 40%, whereas only in 10% of
patients who underwent surgery with SVEF 40%. Other
variables for late mortality included subpulmonary ventric-
ular systolic pressure, a concomitant of increased pulmonary
vascular resistance, and atrial flutter at functional class III to
IV. This paper points out the special expertise necessary not
only to manage these patients but also to perform adequate
surgical valve replacement as well. An accompanying edito-
rial by Bacha (263), a surgeon, points out that this is the
largest modern surgical series published to date in these
patients and emphasizes the demonstrated mandate for an
early move to surgery at a time when SVEF is preserved.
In a related issue, Goossens et al. (264) report on the issue
of transfer of adolescents with congenital heart disease
(CHD) from pediatric cardiology to adult health care. They
describe 794 patients, 58 of which were lost to follow-up.
The investigators’ SWITCH (Self-Management and Well-
Being Improvements by Transitioning Adolescents with
Chronic Disorders in Hospital and at Home) research
program in Belgium studied patients at a tertiary care center
that cares for 27% of Belgian patients with CHD. Of the
794 patients studied, 79% with significant CHD received
follow-up at a tertiary care center and 97.8% of those
patients were successfully transferred to adult CHD pro-
grams. The likelihood of no cardiac follow-up after leaving
pediatric cardiology were male sex and no prior heart
surgery—probably defining the milder spectrum of disease.
Only 2 of 74 patients with complex heart disease (2.7%) and
31 of 448 with moderate heart disease (6.9%) were not inthe follow-up group. This record is far better than most
regions and represents the results of an organized transi-
tioning policy–not without its problems.
A paper from a Pediatric Heart Network investigation
group follows 536 Fontan patients post-operatively (mean
age: 11.9 years), 361 of whom had a fenestration performed
(265). At the time of cross-sectional testing (8  3 years
after Fontan), fenestration remained open in 19%; had been
closed by catheter intervention in 59% and by surgical
intervention in 1%; and 40% closed spontaneously. Patients
with Fontan were taking more medication and had lower
resting saturation. Early post-operative benefits occurred in
the fenestrated group: length of stay was 2.5 days shorter
than without fenestration. The percentage of procedures
including fenestration increased rapidly over the period of
the study. Performance of fenestration, however, was not
associated with changes in exercise performance, functional
health status, or echocardiographic function, although the
patients with persisting Fontan conditions continued to
receive more medications after hospital discharge. The
strategy of leaving the fenestration open has been more
widely adopted.
A population study from the Netherlands analyzed out-
of-hospital cardiac arrest in victims younger than 21 years
(266). With a total of 923 pediatric deaths, there were 233
out-of-hospital cardiac arrest cases, 221 of whom died and
12 of whom survived. The out-of-hospital cardiac deaths
totaled 24% of pediatric mortality. Natural causes (49% of
cases) were the most prevalent, with cardiac causes account-
ing for 39%. Of the 51 victims resuscitated, 12 (24%)
survived; 10 of them had a neurologically intact outcome. A
helpful editorial comment by Chugh (267), a sudden death
specialist, emphasized the overall rate of hospital discharge
being 24% and neurological recovery occurring in 83% of
those cases. He states that renewed emphasis needs to be
placed on community healthcare providers to obtain de-
tailed family histories with appropriate referrals for genetic
screening and counseling. For unexplained sudden death, a
molecular autopsy should become part of the community
forensic investigation to establish familial incidence of
diseases.
A large Canadian population-based study, with 23 years
of follow-up from 1983 to 2005, examines the impact of
pulmonary hypertension combined with CHD on outcomes
and healthcare utilization (268). Of 38,430 adult CHD
patients in the database, 2,212 have pulmonary hyperten-
sion. The greatest impact was in those patients 39 years
compared with those older than 40 years. Morbidity risk
was increased 3-fold, as were hospitalizations or intensive
care rates. There was a doubling of all-cause mortality and
a tripling of morbid complications. As in previous studies,
women had a higher risk of pulmonary hypertension, but
the same risk for death. This study calls for more investi-
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anti-Ro/LA antibody positive women referred for serial
echocardiographic evaluation of fetal AV conduction (269).
They found that 150 fetuses had persistently normal AV
conduction; 15 had AV prolongation, but none developed
progressive heart block. Two of the 15 had neonatal
first-degree block that spontaneously resolved, and 1 has not
progressed on follow-up. In this study, fetal AV prolonga-
tion was not predictive of complete AV block. Close
monitoring of these fetuses can be suggested without
treatment.
A multicenter study (270) reports a 1,648-patient LQTS
registry. The patients included had a QTc of 250 ms, and
the endpoints were a first syncope and subsequent second-
through fourth-syncope episodes between birth and 20
years. Patients with a QT interval 500 ms had a signifi-
cantly higher cumulative probability of experiencing their
first syncope (75% vs. 48%). The rate of subsequent events
also was increased both in those who had QTc 500 ms
and 500 ms (74% and 76%). In childhood, male patients
who had LQT1 had the highest cumulative probability of a
fourth cardiac event (36%), though after the first event, the
probability of a subsequent event in the next 2 years was
increased in all sex and genotype groups (35% to 46%).
After the onset of adolescence, there was an age–sex risk
reversal in female patients, with female patients having
LQT2 manifesting the highest rate of a first cardiac event
38% over 5 years of follow-up) and subsequent events (58%
uring 2 years of follow-up). The risk of a first nonfatal
yncope episode was clearly defined in both groups, but
ther than the female patients with LQT2, the risk associ-
ted with this electrocardiographic marker was attenuated
fter the first event.
An international multicenter coarctation of the aorta
egistry reported comparison of surgical approaches to
tenting and balloon angioplasty in children 10 kg (271).
hey enrolled 350 patients: 217 underwent stent implanta-
ion; 61 had balloon angioplasty; and 72 underwent surgery.
ll showed significant reduction in systolic blood pressure
nd upper to lower extremity systolic blood pressure gradi-
nts. Stenting was superior to balloon angioplasty in low-
ring gradient; surgery was also superior to balloon angio-
lasty in reducing gradient. Surgery was, for the most part,
nastomotic (63%); 17% of patients underwent tube graft
nterposition, 14% patch angioplasty, and 6% subclavian flap
epair. Stent procedures (271) were performed in 217
atients, and 19 required a second stent, either to cover the
ntire coarctation segment or because of stent migration.
atients undergoing stent implantation were significantly
lder and weighed more than balloon angioplasty or surgical
atients, and stent patients had significantly smaller coarc-
ation measurements as a function of body surface area than
alloon angioplasty patients did. In the surgery group, there
as 1 spinal injury; in the stent group, 1 patient developed
arge femoral hematomas, and in 3 patients, stent migration
ccurred during the procedure. Fifty-four patients hadeinterventions; some anticipated as a function of staged
pproach and some for somatic growth. Among the unan-
icipated reinterventions, all except for 1 stent aneurysm
ere because of reobstruction. Wall injury was more often
ncountered in the balloon angioplasty group than in the
urgery or stent groups. Stent patients had lower acute
omplications than surgery patients did, and stent patients
chieved superior short-term hemodynamics. Stent patients
ere also likely to have a planned reintervention for further
ilation or additional stent placement. Stents appear to be
aining in popularity as a primary approach method, espe-
ially because they can be redilated and can avoid some of
he complications that occur with surgery.
A report described a less invasive approach to relieve
evere hypertrophic obstructive cardiomyopathy in children
272). Thirty-two children with a mean age of 11 years and
ean weight of 31 kg had ablation of the septum performed
sing a cool-tip catheter via a femoral artery approach. The
rocedure was guided by transesophageal echo and tempo-
ary pacing electrodes were placed in the right atrium and
he right ventricle to later check whether dual-chamber
acing also decreased gradient. There was 1 procedure-
elated death. Two patients had complete AV block and
equired dual-chamber pacemakers; in 1 of them, the block
esolved within a month. The median pre-procedure pull-
ack gradient of 80 mm Hg decreased to 34 mm Hg. Also,
uring the post-procedure period, there was a reduction in
R in 12 patients, who had varying degrees of systolic
nterior motion. The investigators view the method as
romising and potentially more controlled for tissue de-
truction than alcohol septal ablation is.
besity and Adipose Tissue: Cardiotoxic Effects
besity and cardiac aging. Neimann et al. (273) examined
f obesity causes premature aging of the heart. Right atrial
issue samples were taken from 60 patients undergoing
ardiac surgery, who were subdivided into 4 groups based on
ge (young: 55 years vs. old: 70 years) and BMI
nonobese: 18.5 to 25 kg/m2 vs. obese: 30 to 35 kg/m2).
Young obese patients had phenotypes similar to old obese
and nonobese patients, with higher fasting plasma glucose,
insulin, and leptin levels and increased NT-proBNP, com-
pared with young nonobese patients. Right atrial cardiomy-
ocytes from young obese patients also had impaired mito-
chondrial function with increased oxidative stress, decreased
complex I, and increased markers of apoptosis. These results
suggest that obesity may induce premature aging of the
heart. In an editorial comment, Abel (274) discussed po-
tential mechanisms for these intriguing results. Although
patients with diabetes had been excluded, obese patients
may be at increased risk for developing diabetes so that mild
impairments in glucose tolerance and insulin resistance may
be sufficient to impair mitochondrial function and increase
oxidative stress. Although LV function was preserved,
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and insulin resistance may impair mitochondrial function.
Adipose tissue: location and phenotype. The CV effects
of obesity may vary with inflammatory changes in adipose
tissue, which may have local effects on vascular function and
the atherosclerosis. Local changes in adipose tissue were
directly examined in a series of 3 studies.
Farb et al. (275) obtained abdominal subcutaneous adi-
pose tissue from 109 overweight (BMI 25 kg/m2) and 17
ean subjects. The adipose tissue showed inflammatory
hanges with macrophage crownlike structures in 78% of
verweight subjects, whereas 22% had noninflamed fat.
verweight subjects with inflamed subcutaneous adipose fat
ad higher insulin levels, homeostasis model assessment,
mpaired brachial artery flow-mediated dilation, and ele-
ated expression of inflammatory markers in adipose tissue
clusters of differentiation CD68, leptin, and MMP9) com-
ared with overweight subjects without inflammation or
ean control subjects. Overweight subjects without inflamed
at had intermediate risk factor profiles, indicating that
ubjects of similar weight have additional risks with inflam-
ation in their adipose tissue. Reducing inflammation in
dipose tissue may be a potential therapeutic target.
Virdis et al. (276) compared arteriole function in visceral
at biopsies (obtained during laparoscopic surgery) from 14
everely obese (BMI 48 kg/m2) with 14 nonobese control
ubjects. Obese subjects had higher plasma and vascular
umor necrosis factor-alpha levels with impaired endothelial-
ependent relaxation in arterioles that was associated with
ncreased superoxide production and reduced nitric oxide
vailability. This is a mechanism for visceral fat to impair
ndothelial function in small resistance vessels, which may
ontribute to impaired endothelial function in obesity.
Hirata (277) compared epicardial adipose tissue and
ubcutaneous adipose tissue from the same individual in 38
atients with CAD undergoing coronary artery bypass, and
0 patients without CAD undergoing cardiac valve surgery.
n patients with CAD, epicardial adipose tissue showed
vidence of infiltration by inflammatory macrophages with
n increased ratio of inflammatory to noninflammatory
acrophages and increased expression of pro-inflammatory
ytokines; both correlated with the severity of CAD. These
hanges were not observed in subcutaneous adipose tissue.
atients without CAD did not have evidence of inflamma-
ion in either epicardial or subcutaneous adipose tissue.
hus, local inflammatory changes in adipose tissue are
ssociated with coronary atherosclerosis.
In an editorial comment, Dandona et al. (278) place these
studies in context. Adipose tissue produces inflammatory
ytokines including tumor necrosis factor alpha that con-
ribute to insulin resistance and vascular abnormalities.
hese 3 studies support the concept that adipose tissue has
roinflammatory effects in obesity, with regional effects that
ay contribute to hepatic insulin resistance, systemic in-ammation, and arterial atherosclerotic inflammation. nhemokines in Myocardial Injury and Repair:
re-Clinical Studies
hemokines are chemotactic cytokines that regulate a
omplex series of events after MI from acute inflammatory
hanges to reparative processes. Liehn et al. (279) examined
he role of the CXCL12/CxCr4 signaling pathway in MI in
ice. The CxCr4 receptor and its ligand CXCL12 play a
eneficial role in MI by recruiting progenitor cells, inducing
ngiogenesis, and activating cardioprotective pathways.
xCr4-heterozygous (CxCr4/–) and bone marrow chime-
ic mice had decreased infarct sizes compared with wild-
ype mice. This was associated with decreased inflamma-
ory cell recruitment, delayed monocyte infiltration, as
ell as decreased angiogenesis. In an editorial comment,
rangogiannis (280) discusses the challenges in studying
he role of the stromal cell-derived factor 1/CXCR4 axis,
nd sorting out the complex roles that may be cell type–
nd context-dependent. There is interest in this field
ecause agents such as AMD3100 that target this axis are
linically approved for use in other fields, such as for the
obilization of stem cells.
A state-of-the-art paper reviews major advances over the
ast decade in understanding the role of chemokines in MI
nd identifying potential therapeutic targets (281). Chemo-
ines play an important role in the first few days after MI,
here the inflammatory phase is characterized by neu-
rophil infiltration and the removal of debris. This is
ollowed by a proliferative phase over the ensuing 3 to 4
eeks, where chemokines attract reparative monocytes,
nduce angiogenesis, and recruit stem cells. Finally,
uring the healing phase, chemokines regulate factors to
mprove scar formation and remodeling. An increased
nderstanding of the time-, cell-, and context-dependent
ole of chemokines will provide the potential to identify
ovel targets to improve outcomes.
argeting the Mitochondria in Cardiomyopathy:
re-Clinical Studies
he abnormal generation of reactive oxygen species (ROS)
auses cardiac damage in cardiomyopathies. However, clin-
cal trials with antioxidant therapies have produced variable
r disappointing results. Mitochondria are the major source
f ROS in the heart. Novel mitochondrial targets and
herapies have been identified that may be more effective in
mproving outcomes.
Dai et al. (282) used the Szeto-Schiller (SS)-31 peptide,
hich selectively targets the inner mitochondrial membrane
o scavenge superoxide, hydrogen peroxide, peroxynitrite,
nd hydroxyl radicals. Mice infused with angiotensin II for
weeks developed a cardiomyopathy with increased LV
ass and preserved systolic function, but with abnormal
iastolic function and fibrosis. Mitochondrial protein oxi-
ative damage occurs with increased expression of reduced
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ities were attenuated by SS-21, but not by the nontargeted
antioxidant N-acetyl cysteine. In a second cardiomyopathy
model induced by overexpression of Gq, SS-31 attenuated
ardiac enlargement, preserved systolic function, and re-
uced mitochondrial protein oxidation. These results sug-
est that mitochondrial-targeted antioxidants may be a
seful approach to treat cardiomyopathies.
Maack and Böhm (283) place these results in the broader
ontext of mitochondrial impairments that increase mito-
hondrial ROS in HF, including increased formation of
uperoxide by impairments in electron transport chain
omplexes, and decreased removal of superoxide and perox-
de in the mitochondrial matrix (e.g., by decreased
anganese-superoxide dismutase). Generation of ROS may
ave maladaptive effects on remodeling, or protective effects
uch as enhancing angiogenesis. This duality may underlie
ariable or modest results with nontargeted therapy,
hereas antioxidants that target mitochondrial microdo-
ains may be more effective. It is intriguing to speculate
hat this approach may be useful for treating HF with
reserved ejection fraction, such as is produced in the
ngiotensin II infusion model.
Zhu et al. (284) used the novel approach of dietary nitrate
upplementation to attenuate mitochondrial impairments in
oxorubicin-induced cardiomyopathy. Mice injected with
oxorubicin developed cardiomyopathy after 5 days with
ecreased LV contractility and increased cell death and
issue lipid peroxidation. These abnormalities were attenu-
ted in mice fed dietary nitrate supplementation in their
rinking water (started 7 days before doxorubicin). How-
ver, subcutaneous delivery of nitrate was not effective.
ietary nitrate may be bioconverted and reduced by
acteria in the gut to increase nitric oxide availability
ith protective effects. Daiber et al. (285), in an editorial
omment, note that doxorubicin-induced cardiomyopa-
hy is characterized by mitochondrial impairments that
roduce oxidative stress. Bioconversion of the inert ni-
rate to nitrite by bacteria in the gut may facilitate
onversion to bioactive nitric oxide. The effectiveness of
ral, but not subcutaneous, nitrate supports this concept.
he use of dietary inorganic nitrate to prevent mitochon-
rial dysfunction and reduce oxidative stress may be a
romising area for future clinical investigations.
dentifying a Novel Mechanism
or Aspirin Resistance
esistance to aspirin may mitigate the cardioprotective
ffects of this mainstay therapy. Aspirin reduces platelet
ctivity by inhibiting the cyclooxygenase-1 enzyme in plate-
ets. Mattiello et al. (286) examined aspirin resistance that
ccurs after CABG and identified a new mechanism that
nvolves multidrug resistance protein (MRP)-4. MRP-4
elongs to a family of transporters that remove organic
nions from cells. MRP-4 is localized in dense granules, chich are released after platelet activation. Mattiello et al.
286) identified aspirin as a substrate for MRP-4, which
xtrudes aspirin from platelets. Platelets from patients 5
nd/or 10 days after CABG, compared with healthy control
ubjects, had up-regulation of MRP-4 with reduced effects
f aspirin. Inhibiting MRP-4 pharmacologically (dipyrid-
mole or MK-571) or with simian ribonucleic acid led to
spirin accumulation in platelets with greater cyclooxygenase-1
nhibition. Eikelboom and Hankey (287) indicate that it is
novel observation that aspirin is a substrate for MRP-4,
hich can remove aspirin from platelets to decrease its
ffectiveness. The mechanism by which CABG up-
egulates MRP-4 is unknown, but this may be a mechanism
or increased aspirin resistance.
hronotherapy—Optimizing the Timing of
ngiotensin-Converting Enzyme Inhibition to
mprove Cardiac Remodeling: Pre-Clinical Study
olecular clocks exist in nearly all cells and produce
ircadian variations in biological functions. Martino et al.
288) investigated how the timing of therapy with captopril
nfluences its effect on ventricular remodeling in mice with
ressure overload hypertrophy (transthoracic aortic banding).
aptopril given before sleep was more effective than giving
reatment during awake hours, in terms of decreasing LV
ilation and myocyte hypertrophy and increasing angiotensin-
onverting enzyme messenger ribonucleic acid expression.
hese benefits were unrelated to diurnal changes in blood
ressure or alterations in circadian genes. In an editorial
omment, Jugdutt (289) reviews the concepts in chronobio-
ogical therapy that have emerged over the past decades.
ircadian rhythms have been identified for several variables
elevant for cardiac remodeling, including increases in atrial
atriuretic peptide, growth hormone, and cortisol, renin, an-
iotensin, aldosterone, and catecholamines. Prior studies have
hown the benefits of chronotherapy in managing essential
ypertension. The current study adds that the peak effective-
ess of a short-acting angiotensin-converting enzyme inhibitor
o benefit remodeling occurs when given during sleep.
Although leukocytes appear to play an important role in
he genesis of atherosclerosis, immunosuppression has gen-
rally not shown clear benefits in retarding lesion formation
n animal models of atherosclerosis. Von Vietinghoff et al.
290) studied a novel strategy, using mycophenolate mofetil
o inhibit T-lymphocyte–mediated immunity, resulting in a
ecrease in aortic lesion size in an atherosclerosis-prone
enetic model in mice. These findings suggest the potential
or novel strategies to prevent of treat atherosclerosis tar-
eting interleukin-17.
Genetic causes of dilated cardiomyopathy have received
onsiderable attention in recent years. Diegoli et al. (291)
escribe the prevalence and natural history of X-linked DCM
ssociated with dystrophin defects. The paper alerts the HF
ommunity to the importance of this disorder and suggests that
530 DeMaria et al. JACC Vol. 59, No. 5, 2012
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end-stage HF, but not life-threatening arrhythmias.
Elevated levels of apolipoprotein A represent a vexing
problem in CV medicine with no truly effective treatments.
Merki et al. (292) developed and tested in mice a novel
approach for reducing lipoprotein A levels using an anti-
sense oligonucleotide. Although the effect size was modest,
this approach offers the opportunity to develop a new
pharmacological strategy for treatment of a previously un-
treatable disorder.
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